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Monoclonal anti-DNA antibodies produce various types of glomeru-
lar immune deposits and induce different dlinicopathologic syndromes.
D. V. Viahakos, M.H. Foster, 1. Viachojannis, A. Ucci, and M.P. Ma-
dab, Rena! Division, Patra Univ. Hospital, Patra, Greece, and Depts
of Med. and Patho!., New Eng!. Med. Ctr Hosp., Boston, MA and Re-
na! Electrolyte Section, U. Penn. School of Med. Phi!ade!phia, PA,
USA. Nephritogenic immunoglobulins eluted from individuals with
Systemic Lupus Erythematosus (SLE) cross-react with a variety of fo-
reign and self-antigens, are predominantly IgG and fix complement.
To further investigate the role of isotype, charge, h gene family usa-
ge and binding profile to the pathogenesis of nephritis, 6 monoclonal
anti-DNA antibody-producing hybridomas (mAb) derived from
MRL-lpr/lpr lupus-prone mice were selected and administered IP to
normal mice. After a period of 2-3 weeks, all animals developed both
ascites and/or tumors and serum anti-DNA activity. At that time, uri-
ne protein excretion was measured in 24 hours collections in metabo-
lic cages, the animals were sacrificed and ascites, serum and tissues
were collected for further analysis. The next table summarizes the in
vitro findings of the anti-DNA mAb:
mAb H73 H238 Hl6l H22l 11147 H9
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Both the location of immune deposits and the morphologic and clini-
cal expression of the ensuing disease varied with the administered
mAb; normal appearance, no proteinuria despite elevated serum anti-
DNA titers (1173); diffuse fine granular deposits, enlarged hypercellu-
lar glomeruli and proteinuria (H238); dense mesangial deposits with
mesangial expansion and borderline proteinuria (11161); diffuse den-
se intraluminal and capillary wall deposits, aneurysmal dilatations of
capillary loops, no hypercellularity and severe proteinuria (H22 1);
granular mesangial and subendothelial deposits associated with proli-
ferative glomerulonephritis, diffuse linear staining and proteinuria
(H 147); penetration into cells and nuclear staining, mesangial expan-
sion with mild proliferation and proteinuria (Hg). These results sug-
gest that dominant interactions between subsets of autoAb and renal
antigen(s) rather than their physicochemical properties influence DOLII
the morphologic and clinical expression of disease.
Glomerular expression of transforming growth factor (TGF-a) and
platelet-derived growth factor (PDGF) in experimental anti-GBM dis-
ease. E. Lianos, V. Orfanos, and N. Anagnou, Divisions of Nephro!ogy
and Molecular Biology. University of Crete, Greece. The polypeptide
growth factors TGF-B and PDGF have been cloned and their glome-
rular expression has been described in experimental proliferative
nephritis (J. Clin Invest 86: 453, 1990). A possible cellular origin is
the elicited macrophage which infiltrates the glomerulus in prolifera-
tive forms of nephritis. This work assessed the glomerular gene cx-
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pression of TGF-B and PDGF in a macrophage-dependent (M-D) and
a macrophage-independent (M-I) model of anti-GBM disease. Male
Spruge-Dawley rats received either a single proteinuric dose of rab-
bit(Rb) anti-rat GBM Ig to induce MI anti-GBM disease, or were
preimmunized with Rb IgG and subsequently received non-immune
Rb IgG. Glomeruli were isolated on days 2,4,5,7 and 10 following
administration of the anti-GBM lgG. Total glomerular RNA was iso-
lated and hybridized with 32P-labeled murine TGF-B PDGF cDNA
probes [Sma-I 974bp in PGEM7Z(F) and Ava-I PGEM LIc-sis, re-
spectively]. The intensity of hybridization bands was used as a refe-
rence to quantity expression of TGF-B and PDGF mRNA. There was
no difference in the levels of glomerular TGF-13 and PDGF mRNA
were noted in the M-D model on days 5 and 7 respectively. At these
points increased glomelural infiltration by Ia(÷) macrophages was no-
ted. We conclude that the elicited macrophage is a potential source of
TGF-13 and PDGF in proliferative nephritis and may mediate prolife-
ration in a paracrine manner.
Incidence of focal segmental glomerulosclerosis in adults with mini-
mal change disease: The diagnostic value of repeat renal biopsy. B.
Margellos, Fl. Sotsiou, N. Nikolopoulou, Chr. Christodoulidou, Th.
Apostolou, D. Georgakopoulou, M. Giamalis, and A. Billis, Division of
Nephrology and Department of Pathology, Evangelismos Hospital,
Athens, Greece. According to the literature of the last decade, focal
segmental glomerulosclerosis (FSGS) develops in a small proportion
(0,5-5%) of patients (pts) with minimal change disease (MCD). Howe-
ver, this percentage may be considerably higher since the develop-
ment of FSGS is frequently not diagnosed by renal bopsy. We stu-
died the incidence of FSGS in 24 consecutive pts, 16 to 67 years old,
who presented initially with idiopathic nephrotic syndome, normal
renal function and histologically confirmed MCD. Seven of these pts
were submitted to repeat renal biopsy, 6 to 66 months after the first,
because the nephrotic syndrome either did not respond to the sequen-
tial administration of steroids and cyclophosphamide (2 pts) or re-
sponded initially but relapsed frequently (5 pts). Four of the 7 pts
presented also with progressive decline of their renal function. In all
these four pts, the repeat biopsy disclosed FSGS (an incidence of
16,7% for all pts), while in the remaining three showed again MCD
which was subsequently treated by a further course of cyclophospha-
mide (1 pt) or cyclosporine (I pt). At the end of the follow-up period
(13 to 141 months after the first biopsy and 7 to 66 months after the
second), 3 of the 4 pts with FSGS were on chronic hemodialysis and
the fourth had moderately severe chronic renal failure, while in the
remaining three pts the nephrotic syndrome was in remission (com-
plete in I, partial in 2). In conclusion, in adult pts with MCD: I) It
seems that the incidence of FSGS is higher than that reported in the
literature because it is frequently not diagnosed histologically. 2) The
diagnosis of FSGS has important bearing on the prognosis and the
management of the pts.
Treatment of nephrotic syndrome resistant to steroids with cyclospo-
rin-A (CSA). D. Grekas, H. Kalekou, P. Alivanis, L. Settas, C. Dioudis,
and A. Tourkantonis, First Medical Department, Renal Unit, Universi-
ty Hospital AHEPA, Thessaloniki, Greece. Twenty-two patients with
nephrotic syndrome (NS) resistant to steroids, 13 with idiopathic NS
(group A) and 9 with secondary NS (group B), aged from 19 to 56
years were included in this study. 5/13 patients of group A developed
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on biopsy focal and segmental glomerulosclerosis (FSG), 4/13 mini-
mal change disease (MCD) and 4/13 membranous nephropathy
(MN). 7/9 patients with systemic lupus erythematosus, 1/9 with rheu-
matoid arthritis and 1/9 with Henoch-Schonlein purpura were inclu-
ded in group B. 3/9 patients of group B showed diffuse proliferative
glomerulonephritis (DPGN), 2/9 focal glomerulonephritis (FGN), 3/9
MN and I/I 1 renal amyloidosis (A). All patients received for 3-6
months 1-2 mg/kg body wt prednisolone alone or in combination
with cyclophosphamide and they showed partial or no remission of
the NS. CSA was given per os in the dosage of 6 mg/kg body wt for
3-6 months. Patients with MCD (group A) and DPGN (group B) sho-
wed full remission of the NS while the rest showed partial remission.
Some patients with FSGN and MN showed also a slight deterioration
of renal function. We conclude that the treatment of NS resistant to
steroids with CSA is successful for patients with MCD and DPGN.
Cyclosporin and children with nephrotic syndrome (NS). C. Stefani-
dis, A. Mitsioni, and K Michelis, 'A. and P. Kyriakou" Children Ho-
spital, Athens, Greece. Corticosteroid administration is unsuccessful
in a small percentage of children with NS and these patients (pts) re-
quire an alternative management. Cyclosporin (C) was given for 8-25
months in 11 children (5 with steroid dependent and 6 with steroid
resistant NS) 2.3-12.6 years of age. The follow-up period was 1-4.6
years. 4 pts had minimal-change disease, 4 mesangioproliferative gb-
merulonephritis and 3 focal-segmental glomerulosclerosis. Pts recei-
ved an initial dose of C 6 mg/kg/day, which was adjusted to maintain
plasma levels between 100-500 ng/ml. All pts received prednisolone
(1.2 mg/kg/day) progressively reduced to 0.3 mg/kg/day. 2/5 pts with
steroid resistant NS had a significant decrease of proteinuria and 3
had a sustained remission. All pts with steroid dependent NS remai-
ned relapse-free while receiving full dose of C, however 4/6 relapsed
when C was tapered. Nephrotoxicity was noticed in 4 children and
hypertrichosis in 6, These side effects were reversed on withdraw of
C. In conclusion cyclosporin was effective in children with NS. Howe-
ver in children with dependent NS the medicine in combination with
low-dose steroids has to be administered for prolonged periods.
Sodium-lithium countertransport activity is related to deterioration
of renal function In IgA nephropathy. P. Kontessis, T. Tariq, R. Fried-
man, F. Moro, D. G. Williams, and G. C. Viberti, Unit for Metabolic
Medicine and Renal Unit, Guy's Hospital, London, UK. In IgA neph-
ropathy renal function can remain stable or deteriorate progressively.
Deterioration seems to occur in the patients with initially higher
blood pressure (BP). An hyperactivity of the red blood cell sodium-
lithium countertransport (NaLiCT) has been associated with the pre-
disposition to essential hypertension. We measured NaLiCT in a
group of 16 patients (13 M: 3 F), aged 21 to 60 years, with IgA neph-
ropathy who successively attended the outpatient department of the
Renal Unit over a 6-month period. The patients' records were revie-
wed for serial measurements of BP, 24-hours urinary protein excre-
tion, glomerular filtration rate (5 lCr-EDTA), creatinine, urea and
electrolytes. Measurements of fructosamine ruled out diabetes melli-
tus. In a univariate analysis, NaLiCT was significantly correlated
with the slope of GFR (r —
—0.63, p 0.008), as well as with systolic (r
0.68, p 0.008) and diastolic blood pressure (r 0.51, p = 0.06) at
diagnosis. A significant correlation was also found with current systo-
lic (r 0.60, p 0.022), and diastolic (r 0.58, p 0.031) BP. In a
stepwise multiple regression analysis with the rate of decline of GFR
as the dependent variable, independent correlations were shown with
NaLiCT (p — 0.0026), and current urinary protein excretion only (p
0.02). Other variables such as initial and current GFR and systolic
and diastolic blood pressure were not correlated with the slope of
GFR. Our results suggest that the activity of NaLiCT, an indicator of
risk for essential hypertension, is associated with the deterioration of
renal function in IgA nephropathy.
Diagnostic significance of the detection of anti-neutrophil cytoplas-
mic antibodies (ANCA). D. Hadjiyannakos, K. Terzoglou, M. Econo-
mou, N. Nikolopoulou, M. Maragou, P. Stavropoulos, Z. Rodoussaki,
S. Athanasiadou, P. Dantis, and A. Billis, Dividions of Nephrology, Im-
munology and Histoco,npatibility, and Rheumatology, Evangelismos
Hospital, Athens, Greece. Although the presence of ANCA has been
related to various autoimmune disorders, their diagnostic value is
mainly limited to small vessel vasculitis, that is, microscopic polyar-
teritis (MP) and Wegener's granulomatosis (WG). We evaluated the
clinical significance of these antibodies by examining the sera of 90
patients (pts) who were admitted to the hospital for systemic lupus
erythematosus (26 pts, 9 with nephritis), MP with renal involvement
(17 pts, 9 in the acute phase), primary and secondary glomeruloneph-
ntis (14 pts), rheumatoid arthritis (8 pts), hypersensitivity vasculitis
(6 pts) WG (4 pts, 3 in the acute phase) and miscellaneous disorders
(15 pts). In 60 pts, including all those with MP and WG, the diagnosis
was confirmed by biopsy of an involved organ. As a control group
were used 30 apparently healthy donors. The detection of ANCA was
done by two techniques: a) by indirect immunofluorescence which
identifies a cytoplasmic (c-ANCA) and a perinuclear (p-ANCA) pat-
tern of fluorescence, b) by enzyme-linked immunosorbent assay (ELI-
SA) using as antigens the proteinase-3 (PR 3) and the myeloperoxida-
se (MPO) of the neutrophils cytoplasm. Serum positive for ANCA, by
one or both techniques, were found in 11 pts who were all in the acute
phase of their illness (table).
ANCA (+) Immunofluorescence ELISA
patients c-ANCA p-ANCA anti-PR3 anti-MPO
MP 9 2 5 2 7
WG 2 2 0 2 0
In the remaining 79 pts, as well as in the controls, the detection of
ANCA was negative. These findings: 1) Confirm that ANCA are de-
tected mainly in the acute phase of MP and WG, 2) Suggest that there
is a positive correlation between p-ANCA and anti-MPO both of
which are mainly found in MP.
Frequency and possible prognostic role of HLA antigens in microsco-
pic polyarteritis (MP) with renal Involvement. D. Hadjiyannakos, M.
Siakotos, H. Fappa, K. Tarassi, N. Nikolopoulou, S. Michael, Chr. Ka-
ninis, Gr. Vosnides, C/zr. Papasteriades, and A. Billis, Division of
Nephrology and Laboratory of Immunology, Evangelismos Hospital,
Division of Nephrology, Laiko Gen. Hospital, Athens, Greece. The pur-
pose of this work was to study the frequency of HLA antigens in pa-
tients with MP and renal involvement and to assess a possible role of
HLA-antigens in susceptibility to or protection against the MP as well
as to the outcome of the disease. Thus, the HLA-A,B and DR antigens
were determined in 23 patients (10 males, 13 females) aged 30-77
years, presenting with MP and renal involvement, histologically con-
firmed. 405 apparently healthy individuals (190 males, 215 females),
aged 18-65 years, were used as controls. The patients, compared to
the controls, showed: 1) An inceased frequency of HLA-Ab0 (26% vs
11,3%, p < 0.05, Pc =NS, relative risk RR 2.75), HLA-Al 1(26% vs
9.6%, p < 0.025, Pc = NS, RR 3.31) and HLA-DR5 (52.1% vs
36.4%, p NS, RR 1.90) antigens, and 2) a decreased frequency of
HLA-DR3 antigen (4.3% vs 24.1%, p <0.025, RR = 0.14). Six Out of
7 patients who had not responded to the therapy and eventually died
or were started on hemodialysis had the HLA-DR5 antigen. Our fin-
dings, although based on a small number of patients, indicate that: 1)
There is no strong correlation between HLA antigens and the suscep-
tibility to MP with renal involvement, 2) The presence of HLA-DR3
antigen may play a protective role against the disease, and 3) The
presence of HLA-DR5 antigen may be considered as a bad prognostic
index for the outcome of the disease.
Clinico-pathological evaluation of renal function after Intravenous
pulse cyclophosphamide in systemic lupus erythematosus (SLE). D.
Georgakopoulou, FL Sotsiou, N. Nikolopoulou, M. Maragou, Ch. Chri-
stodoulidou, D. Szavrianaki, P. Danlis, and A. Billis, Division of Neph-
rology, Rheumatology and Pathology, Evangelismos Hospital, Athens,
Greece. The therapeutic effect of intravenous pulse cyclophosphaini-
de on the nephritis of SLE was prospectively studied in 10 patients
(pts) (9 F, I M), 20 to 39 years old. Before treatment, 5 pts presented
with nephrotic syndrome (NS) and 5 with asymptomatic proteinuria
and/or microscopic haematuria. Five of 10 pts had also impaired re-
nab function. The initial renal biopsy showed in 5 pts diffuse prolife-
rative glomerubonephnitis (GN), in 3 pts mixed lesions and in 2 pts
sclerotic lesions. The cycbophosphamide was given intravenously in
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monthly pulses (750 mg/rn2 of surface body area) for six months and
subsequently in the same dosage 3-monthly. All pts also received
prednisolone (0.5-1 mg/kg body wt daily) which, when their condition
had been stabilized, was gradually reduced. In 2 pts with NS and im-
paired renal function cyclophosphamide treatment was discontinued
after the first 3 months because of severe persistent leucopenia (1 pt)
and refusal of treatment (1 pt). The remaining 8 pts continued their
treatment for 24-36 months and then were submitted to a second re-
nal biopsy. At the end of treatment, renal function has become nor-
mal or had been considerably improved in 3 of the 5 pts who comple-
ted their treatment, while the NS was in remission in 2 of the 3 trea-
ted pts. On the second renal biopsy, 4 of the 5 pts with diffuse prolife-
rative GN (the fifth pt did not have a second biopsy) showed evolu-
tion of the histologic lesion to membranous (2 pts), focal proliferative
(1 pt) and mesangioproliferative GN (1 pt) with a parallel decrease of
the activity index of the disease from 12.5 to 3.5 (mean value), while
the chronicity index remained unchanged. The only significant side-
effect of cyclophosphamide was the persistent leucopenia in 1 pt
which led to discontinuation of treatment. In conclusion, intravenous
pulse administration of cyclophosphamide in our pts improved consi-
derably both their renal function and the pattern of glomerular histo-
logical lesions of SLE.
The effect of an acute oral protein load on urinary albumine excretion
in subjects with a solitary kidney. N. Papagalanis, M. Gennadiu, A.
Karabatsos, K. Fainekos, M. Elisaf A. Kourti, A. Zacharof K. Siamo-
poulos, and Th. Mouniokalakis, Department of Nephrology Red Cross
Hospital of Athens, Athens, Greece, Department of Endocrinology Red
Cross Hospital of Athens, Athens, Greece, Department of Indernal Me-
dicine University of loannina, loannina, Greece, Department of Inder-
nal Medicine University of Athens, Athens, Greece. The effect of an
acute oral protein load (OPL) of 150 g on urinary albumine excretion
(UAE) was determined in 29 subjects (PTS) aged 22-75 years (mean
54.14) with negative albustix tested urines who had undergone unila-
teral nephrectomy 15 days to 52 years ago (96.9 145.5 months) and
in 16 normal volunteers (CTR) aged 25-55 years (mean 47.7). Pa-
tients with one kidney for more than 10 years (9 PTS aged 58.38
3.23 years with a mean time after nephrectomy 282.75 58.34
months-PTS I) had lower creatinine clearance (Cr) and higher mean
blood pressure (MBP) compared with either the PTS with one kidney
for less than 10 years (21 PTS aged 52.53 2.9 years with a mean
time after nephrectomy 26.1 19 months-PTS II) or the CTR (Cr
values: 51.75 5.8, 74.48 4.9 and 100.33 7.5 ml/min/l.73 m2,
p = 0.0007, for PTS I, PTS II and CTR respectively. MBP values:
102.5 3.6, 95.82 3.0, and 86.8 2.6 mm Hg, p = 0.03, for PTS
I, PTS II and CTR respectively). UAE was higher in PTS I compared
with either PTS II or CTR at both the basal state (26.5 5.0, 11.4
1.7 and 9.4 2.0 jig/mm, p 0.0005, for PTS I, PTS II and CTR
respectively) and after OPL (29.0 5,0, 13.1 1,8, and 10.8 2.4j.tg/min, p 0.0005, for PTS I, PTS II and CTR respectively). Howe-
ver, the magnitude of postpradial increase in UAE was significant (p
= 0.009) in PTS II only. An exponentialy negative correlation be-
tween UAE and Cr (r —0.55, p = 0.002) and an exponentialy too
but positive correlation between UAE and the time since nephrecto-
my (r = 0.65, p =0.0001) was apparent in the total population of PTS
studied. Serum creatinine was higher in PTS I compared with PTS II
and with CTR at either the basal state (126.0 17.0, 93.9 6.0, and
80.5 5.0 jimol/liter, p = 0.01, for PTS I, PTS II and CTR respecti-
vely) or after OPL (143 17.7, 124.8 8.0 and 113.0 8.3 jimol/
liter, p = 0.05, for PTS I, PTS II and CTR respectively), however the
increase in serum creatinine after OPL was significant in either PTS I
(p =0.02), PTS II (p = 0.003), and CTR (p = 0.006). Urinary creatine
was lower in both PTS I and PTS II compared with CTR at the basal
state (7.5 1.6, 8.2 0.7, and 15.2 4.0 jimol/min, p = 0.01 for
PTS I, PTS II and CTR respectively); however urinary creatinine was
increased (to 10.3 1.0, p = 0,02, and to 17,1 3.0 in PTS II and
CTR respectively) in PTS 11 and in CTR while it was reduced to 4.8
1.0 l.tmol/mjn in PTS I after OPL. Fractional excretion of sodium
was higher in PTS I compared with either PTS II or CTR both at the
basalstate(ll.4 2.0, 10.0 l.2,and4.6 0.4%,p=0.l,forPTS
I, PTS II and CTR respectively) and after OPL (14.1 4.1, 10.1
1.5, and 4.8 0.7%, p = 0.008, for PTS I, PTS II, and CTR respecti-
vely). Urine volume was not different between the three groups at the
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basal state but it was reduced after the OPL (from 1.1 0.6 to 0.63
mI/mm, p = 0.05) in PTS I only. The reciprocal of serum creatinine(SCr-') was negatively, exponentialy, correlated to the time since
nephrectomy in the total population of PTS studied, (r =
—0.43, p =
0.02), this correlation was positive (r = 0.7, p = 0.0004) in PTS 11 and
negative (r = —0.8, p = 0.01) in PTS I. Multiple regression analysis
revealed that this relationship of SCr' with the duration of unineph-
nc state (p = 0.004) was indepentent from age (p = 0.7) or MBP (p =
0.5) in PTS II. However, by steped selection of variables, MBP appea-
red to be a significant factor determining the rate of decline of renal
function in PTS I (p = 0.01). These results indicate that the UAE after
an extremely high OPL increases in uninephnic subjects who are in
the first decade after nephrectomy, and have CCr values higher than
50% of normal. They also suggest that uninephric subjects are in in-
creased risk for developing renal insufficiency after 10 years of neph-
rectomy, due to hyperfiltration present during the early years after
nephrectomy.
An intelligent computer-based system for the diagnosis and manage-
ment of the acute renal failure. S. Markou, A. Diamantopoulos, D.
Skarpetas, A. Kosmopoulos, D. Karayianis, and A. Doulis, Department
of Nephrology, General Hospital of Patras "Agios Andreas" Patras,
Greece. Acute renal failure can arise from a multitude of causes. With
few clinical clues, physicians must recognize the common settings in
which acute renal failure develops and must order appropriate tests
promptly. We developed a software, capable to provide significant
diagnostic and therapeutic problem-solving assistance, in the case of a
patient with acute renal failure, to the practicing physician. We used
as the basis for our software an event-driven, message-based language
with object-oriented features, which operates with a Graphics User
Interface (Windows 3.0). This computer program has windows, icons,
pull-down menus, buttons, dialog boxes, crisp test and standout gra-
phics. It's able to work equally well with either a keyboard or mouse
and take advantage of the power hypertext technology. This software
designed for using by the non-expert, which has a role in the manage-
ment of acute renal failure, demonstrated also the potential power of
hypertext and multimedia concepts in electronic medical publishing.
Finally, as an intelligent tool helps any physician, which is a novice
programmer, to become productive, by interfering with the knowled-
ge base of the acute renal failure.
Neuroleptic malignity syndrome (NMS) and acute renal failure
(Description of a rare case). P. Evangelou, Ch. Kaisina,s, *G Voulgari-
dis, H. Giousef K. Ntaitzikis. and K. Hatzikonstantinou, Renal De-
partment of General Hospital of Veroia, *psychiatric Department of
General Hospital of Veroia. Veroia, Greece. The NMS was firstly des-
cribed by Delay and Denicker in 1968. The cause of the NMS are
considered to be the providing of neuroleptics or the abrupt pause of
antiparkinson drugs. The typical presentation of patients with this
syndrome is: high temperature, generalised rigidity, tachypnea, tachy-
cardia, hypertension, sedation, disorder of concience-coma, and is
confirmed by laboratory findings as: increasement of CPK, LDH,
SOOT, SGPT and leucocytosis with dominance of the polymorpho-
nuclears. A 57-year-old man with an 8 years history of schizoaffective
disorder treated with neuroleptics, antidepressives and sometimes an-
tiparkinsonic drugs, was admitted in our department. 7 days ago he
has been hospitalised in a psychiatric clinic for a relapse of his disea-
se. At the moment of his arrival he presented anuria by 4 days and the
clinical and laboratory examinations revealed: arterial pressure 180/
110 mmHg, 110 pulses/mm, fever 38,5° C, urea 390 mg%, creatinine
17.7 mg%, Ca 6,4 mg%, P 9.4 mg%, K 6.2 mEq/liter, Na 129 mEq/
liter, CPK 2134 U/liter, LDH 554 U/liter, SGOT 109 U/liter, SGPT
112 U/liter, ac. uric 14.3 mg% and leucocytes 13600/mm3 with poly-
morphonuclears 81%. From his history and the laboratory findings
we put the diagnosis of NMS. We stopped previous therapy, we ap-
plied extrarenal support and pharmaceutical therapy with diazepam.
Despite the fact that the diuresis was restored and the therapy with
haemodialysis was effective the patient died after 7 days without ac-
quiring his concience. This case is presented because is rare, only six
cases have been described in Greek literature, and our case is the only
one presented with acute renal failure requiring haemodialysis.
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Life-threatening hyperkalemia: risk factors and prognosis, S. Anto-
niou, N. J-fatzisavvas, G. Kyriazopoulos, S. Tourtouris, and A. Dimi-
triadis, 1st Dept. In!. Medicine, Ag. Dimitrios Hospital, Thessaloniki,
Greece. Increased incidence of hyporeninemic hypoaldosteronism
(old age, DM, etc.) and vast use of drugs affecting the renin-
aldosteron system, may influence the spectrum of risk factors, as well
as, the prognosis of hyperkalemia (HyperK). Thirty four patients
(1.2% of the admitted 21o, l3o) with HyperK (K: 6,5-10.0 mEq/liter),
mean age 71 ys (range 39-92, 73.5%> 65) were studied. Renal failure
(24 CRF, 6 ARF), acidosis (17/26 with pH < 7.35), D. Melitus (15)
and drugs such as CEI (12), amiloride (4), spironolactone (4), were
stated as causative factors for HyperK. Possibly digitalis and other
drugs contributed. K levels were correlated with pH (r = —0.406, p
0.39) and HCO3 (r = —0.399, p 0.044). Intensive treatment (5 with
peritoneal dialysis) reduced K from 7.29 0.86 to 6.01 0.86 (p <
0.044) in 3-24 hours. Only 2 out of 8 deaths were due to HyperK.
Elderly with mild CRF are prone to life-threatening HyperK, mainly
when acidosis and/or DM are present, while consumption of multiple
drugs may contribute. Intensive treatment can reduce morbidity. Fi-
nal prognosis is influenced mainly by underlying diseases.
Long acting antihypertensive agents. P. Koureta, F. Ageleli, A. Kot-
sianis, et a!, Panarcadian General Hospital, Department of' Nephrolo-
gy, Tripolis, Greece. Antihypertensive activity and side effects of Pe-
rindopril (P) and Nitrendipine (N) were evaluated in a total of 73
patients with mild, moderate or severe hypertension for a period of
3-20 months. Fifty-two patients (29 men, 23 women; 28-67 years;
mean 54.2) were treated with the ACE inhibitor P; mean daily dose
5.4 mg once daily. In 34 of them (65%) a diuretic was also necessary.
In two patients an allergic reaction stopped the treatment. Twenty
one patients (1 3 men, 8 women; 48-81 years; mean 63.2) were treated
with calcium entry blocker N; mean dose 25 mg once daily. In 8 pa-
tients diuretics were also added in the treatment. Three patients had
headaches and one oedema of the lower exremities. The mean blood
pressure of all the hypertensives was 172/106 mmHg (± 17,3/8 SD)
before treatment and 138/87 mmHg (± 18,6/7 SD) 2 months later.
No pathological laboratory data were registered. Five patients denied
compliance. Our data indicate that P and N are effective and safe
agents with good response after 20 months and good compliance be-
cause of the convinient once daily dose.
Relationship between metal ions Ca Mg4 K' Na4 during the sud-
den changes of arterial pressure (AP) in man. Th. Galeas*, D. Mylo-
nas*, S. Mylonas*, Hr. Bardas*, N. Tsianas**, and M. Lemoni***, B'
Internal Medicine Clinic*, Artificial Kidney Unit**, Microbiology
Dept***, Trikala General Hospital, Greece. The purpose of the work
was to study the metal ions Ca Mg K4 and Na4 during the sudden
changes of AP. Material of the study were 27 renal patients in the
artificial kidney unit, 17 males, 10 females, mean age 54.74 11.73.
The 6 month study included three stages. In the first stage, in a state
of relaxation, the AP of all patients was measured. In the second and
third stages AP of the patients who manifested signs of sudden eleva-
tion or fall of AP without medical or any other intervention during
hemodialysis was also measured. In all three stages measurement of
blood ions followed. Paired t-test method was used for the analysis of
the results.
Total number of
examined (27)
serum(mmol/l)
Ca"±SD
serum(mmolIl)
Mg4+±SD
serum(meq/l)
K±SD
serum(meqll)NafSD
1, Relaxation
(normal rates)
1.14 0.15
1.14.1.30
1.02± 0.1
1.02-1.05
5.46 0.71
3.5-5
141.7 4.03
135-145
2. Sudden eleva-
tion of AP
1.30 0.15
t 4.92
1.0± 0.88
1 2.81
5.5 1.00
1 = 6.82
145.33 3.31
1 = 2.07
3. Sudden faIl
of A?
1.27 0.24
t = 2.22
0.82± 0.13
t = 3,82
3.5 0.29
1 6,15
134.4 1.51
t —2.01
NS p < 0.05 p <0.01 NS
In conclusion: 1) The sudden elevation or fall of AP during hemodia-
lysis showed a relation with the changes of Ca' Mg' K' concentra-
tions and seems to be independent of Na4 concentrations 2) It can be
said that metal ions Ca4 Mg44 K4 and Na' should also be examined
as possible regulators of AP.
Serum fructosamine (SF) measurement in diabetic patients on chro-.
nic haemodialysis (HD). D. Arvanitis, P.S. Kontessis, E. Iliopoulou, P.
Parigori, E. Georgoussi, and I. Bossinakou-Papathanassiou, Renal
Units, Amalia Fleming and Alexandra Hospitals, Haematological La-
boratory, Hippokration Hospital, Athens, Creece. Glycosylated hae-
moglobin (HbA1) levels in diabetic patients on HD have been clai-
med to be affected by anaemia and urea metabolic products. Serum
fructosamine (SF) measurements could therefore be a better indicator
of glycaemic control, We have studied SF, HbA1, blood glucose, se-
rum protein, blood urea and creatinine in 15 non-diabetic and 11 dia-
betic patients on HD. Blood samples were taken before and after HD
for 4 consequent weeks. Group of 13 healthy volunteers has been
used as control, Overall SF and HbA1 concentrations were signifi-
cantly higher in diabetics than in non-diabetic renal patients (4.5
0.30 vs 2.5 0], p <0.001 and 11,50 0.44 vs 7.5 0.22%, p <
0.001 respectively). HbA1 concentration was higher in non-diabetics
on HD compared to the control group (7.56 0.22 vs 6.5 0,14%, p
< 0.001). SF correlated well with the mean blood glucose levels de-
termined 1 and 2 weeks before (r — 0.708, p < 0.01) in diabetics on
HD but not in non-diabetics on HD. HbA1 was not correlated to ante-
cedent blood glucose in any group. Multiple regression analysis revea-
led that SF had a better correlation with the antecedent blood glucose.
No changes in SF and HbA levels have been shown post-dialysis.
Our results suggest that serum fructosamine measurement provides
reliable information on a short-term glycaemic condition in diabetic
patients on 1-ID.
Nutritional status, apolipoprotein levels and lipoprotein Lp (a) in
diabetics on chronic haemodialysis (HD). P.S. Kontessis, M. Panayo-
tou, I. Bossinakou, N. Papageorgakis, A. Melpidou, D. Roussi, I. Grap-
sa, E. Georgoussi, and N. Zerefos, Renal Unit, Alexandra Hospital,
Haemolological Lab., Hippokration Hospital and Biochemical Lab.,
Evangelismos Hospital, Athens, Greece. Malnutrition has been repor-
ted in uremic patients undergoing HD. Nutritional assessment has
not been clearly defined in diabetic (D) patients on HD. The nutritio-
nal status of 14 D patients (10 males, 4 females) on HD was compa-
red to a group of 17 non-diabetic (ND) patients (11 males, 6 females)
well matched for age and duration of HD. Anthropometric measure-
ments (body mass index BMI, arm circumference AC) were made
using standard techniques and diet was assessed by three-day dietetic
diary. Protein intake was higher in D than in ND patients on HD
(8.16 0.1 vs 0.87 0.07 g/kg/day; p < 0.01) while caloric intake
was not different (23.9 1.9 vs 23.4 1.6 Kcal/Kg/day). Haemato-
crit (28.5 0.66 vs 31.2 1.5%; p <0.01) and vitamin B12 (824
88 vs 1636 126 pg/mI; p <0.05) were lower in D patients. Apo A-I
was lower in diabetics (13.8 11.1 vs 154.6 5.8 mg/dl; p < 0.05).
BUN, serum creatinine, serum albumin, folic acid, ferritin, transfer-
rin, C3 and C4 were similar in both groups. Turberculin test was nega-
tive in 54% of D and 59% of ND patients. Metrices of coefficient
correlation revealed that BMI was correlated with plasma carnitine
levels (r = 0.86, p < 0.01) and phosphate (r 0.91, p < 0.01) in D
patients. Stepwise multiple regression analysis with plasma camitine
and transferrin as dependent variables showed correlations with BMI
(p <0.01) and AC (p <0.05). Neither nutritional intake nor anthro-
pometric measurements were correlated with the duration of HD.
Conclusions: 1) Diabetics of HD are in better nutritional status com-
pared to the non-diabetics. 2) Plasma carnitine and transferrin are
predictors of nutritional status in diabetics on HD.
The importance of aminoacids in the cognitive function in regular
haemodialysis patients. D. Kabadias, S. Pelidou, M. Dima, K. Barbou-
us, and A. Belogiannis, Hemodialysis Unit and Neurological Clinic,
General Hospital of Serres, Greece. It is well known that the pathoge-
nesis of disequilibrium syndrome, in chronic haemodialysed patients
is related to many factors, as electrolyte disturbances, acute changes
at the blood levels of urea and creatinine, disturbances of the pH,
haemodynamic changes, amiioacid losses etc. The clinical manifesta-
tions of this syndrome are related mainly to disturbances of the cere-
bral function. In an effort to study the beneficial effect of i.v. infu-
sions of aminoacids for prevention from the occurrence of the dis-
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equilibrium syndrome, we studied 11 patients with mean age 69
years, who were on a program of chronic haemodialysis with acetate
for 6 to 132 months. Each patient was assessed 5 minutes before and
after each HD session (with acetate or with acetate plus a solution of
aminoacids and sorbitol) by EEG, neuropsychological sceening(MMSE) and clinical neurological examination. After the HD with
acetate plus aminoacids 46.6% of the EEGs improved, 18.2% deterio-
rated and 36.3% remained unchanged. The neurophychological scree-
fling showed: 63.6% improvement, 18.2% deterioration and 18.2%
without any change. Contrary to this after the acetate HD none EEG
improved, 72.7% deteriorated and 27.3% remained unchanged; at the
same time by neurophychological screening we had 36.4% with im-
provement, 63.6% with deterioration and none without any change.
The clinical neurological assessement showed no signiflicant change
with both methods. In conclusion it appears that the i.v. infusion of
aminoacids at the end of the HD with acetate prevented significantly
the appearence of the disequilibrium syndrome.
Pre-operative localization of the parathyroid glands. A comparison of
ultrasound and operative findings. G. Zavos, A. Kostakis, K. Revenas,
St. Kyriakidis, B. Apostolopoulos, E. Koulentianos, P. Giagow, E. Mi-
siakos, and Gr. Vosnides, Transplantation Center, Latkon General Ho-
spital, Athens. Greece. The pre-operative localization of the parathy-
roid glands, can be of significant help to the surgeon. Fifty two, of 123
pts who underwent parathyroidectomy in our unit between Jan. '89
and October '91, were submitted to preoperative ultrasound examina-
tion of the neck. This examination was performed by the same radio-
logist and its findings were compared to the operative ones. Ultraso-
nographically, 4,3,2,1 and no glands were visualized in 12 (24.5%), 7
(14.3%), 16(32.7%), 10(20.4%) and 4(8.2%) pts respectively. In each
of the 2 pts with the recurrence of the disease 1 gland, was visualized
while in the third Pt a false positive result was observed. In five pts
totally a false positive visualization of glands was observed. During
surgical exploration 4,3,2,1 and no glands were located in 38 (77.5%),
8 (1 6.3%), 3 (6.2%), 2 and 1 pt respectively. Totally, of the 184 surgi-
cally recognized glands, 113 (61.4%) were located ultrasonographical-
ly. The ultrasonographic localization of the glands was mainly related
to their position and size. It is conluded that pre-operative ultrasono-
graphic examination of the neck, when done by experienced hands,
provides substantial help to the surgeon. However, thorough know-
ledge of the anatomy of the region is of the outmost importance.
Effect of parathyroid hormone and 1,25(OH)2D3 administration on
T-lymphocytes and their expression of interleukin-2 in hemodialysed
patients. Ch. Stathakis, M Choremi, J. Boletis, A. Iniotaki, B. Viglis,
A. Lambropoulou, D. Stamatiades, A. Kostakis and Gr. Vosnides, Divi-
sion of Nephrology and Transplantation, Immunology Dpt Laikon Ge-
neral Hospital, Athens, Greece. The purpose of this study was the in
vivo investigation of the in vitro findings that parathyroid hormone
(PTH) and 1 ,25(OH)2D3 are immunomodulators. T-cellular immu-
nity was evaluated in 9 adults on regular hemodialysis (HD) who un-
derwent parathyroidectomy (PTX) due to secondary hyperparathy-
roidism. PTH levels were determined with RIA and T-celI subsets
(CD3, CD4, CD8), as well as the expression of interleukin — 2 recep-
tors on CD4 and CD8 (IL-2RICD4, IL-2R/CD8) were determined by
monoclonal antibodies (Becton Dickinson) and flow cytometry, befo-
re, 8 days and 38 days after PTX. Administration of l,25(OH)2D3
(0.5 sg/d, per os) was initiated on the 8th post PTX day. Nine normal
volunteers age and sex matched were used as controls. Our results
showed that 1) there were no differences regarding CD3, CD4, CD8
and CD4/CD8 between controls and HD pts before PTX. 2) On the
8th post-PTX day, CD3 values were higher than pre-PTX (p = 0.02),
CD4 higher than pre-PTX and controls (p = 0.03). 3) After admini-
stration of 1,25(OH)2D3 for 30 days (38th post-PTX day) CD3 and
CD4 remained unchanged compared to the 8th post-PTX day, while
CD8 were reduced and CD4/CD8 ratio significantly increased com-
pared to pre-PTX (p 0.005) the 8th post-PTX day (p <0.05) and
controls (p = 0.007). 4) IL-2R/CD4 and IL-2RJCD8: a) were signifi-
cantly higher in HD pts, prior to, on the 8th and 38th post-PTX day
than in controls (p < 0.03). b) on the 8th post-PTX day IL-2RICD4
and IL-2R/CD8 were higher than pre-PTX. c) on the 38th post-PTX
day both IL-2RICD4 and IL-2R/CD8 decreased compared to the 8th
post-PTX day (p = 0.04, p = 0.03 respectively). Our results indicate
that in HD pts, different levels of PTH and 1,25(OH)2D3 administra-
tion affect T-cell subsets and IL-2R expression on CD4 and CD8.
Serum procollagen type-I as biological parameter of bone metabolism
in hemodialysis-preliminary results. G.E. Digenis, M. Christophoraki,
A. Papantoniou, M. Mavrikakis, V. Papantoniou, E. Samuilidi, N. Ze-
refos, and S. Moulopoulos, Hemodialysis Unit, Therapeutic Clinic,
Athens Medicine School, Biochemistry and sections of
"Alexandra" Hospital, Athens, Greece. The polypeptide procollagen
type-I (Proc-I) is a precursor of collagen type-I which accounts for
more than 90% of bone organic matrix. In order to evaluate this para-
meter in hemodialysis (HD), sera from 12 HD pts (10 males and 2
females, aged 53 5.4 yrs, x SEM)who were dialysed for 62 12
months, were examined in comparison to 11 matched controls. With
the exception of phopshate binders, no medication was taken by the
patients for at least 2 weeks. None suffered from liver disease. Proc-I,
along with serum calcium, phosphate, alkaline phosphatase, total pro-
tein, albumin and intact PTH, were determined at the beginning, 90'
and the end of dialysis. Serum Proc-I levels were significantly higher
in dialysed pts (188 17 vs 85 13 tg/liter of controls) and there
was a positive linear correlation between Proc-I and serum PTH le-
vels (N:36, r:0.445, p < 0.01). Moreover, there was a progressive de-
crease in serum Proc-I levels during dialysis session. As a result,
Proc-I was significantly lower at the end of dialysis (p < 0.01). It is
concluded that the high levels of Proc-I in dialysis pts are positively
correlated with serum PTH. Hemodialysis decreases serum Proc-I le-
vels by an unknown mechanism which needs further study.
Evaluation of renal osteodystrophy (ROD) with calcium kinetic stu-
dies. P. Kurz, T. Tsobanelis, P. Roth, E. Werner, +J. Vlachojannis, *H.
Malluche, and P. Grutzmacker, II. Med. Klinik, St. Markus Hospital
and GSF, Frankfurt/M, Germany, *Univ. of Kentucky, Lexington,
USA, +Rion Univ., Patras, Greece. The manifestation of uremic bone
disease in not uniform and differences in calcium (Ca) metabolism
may be associated with the histological patterns observed. We studied
43 pts on maintenance dialysis treatment with biochemical, histologi-
cal and Ca-kinetic parameters. A double isotope technique (45Ca and
47Ca) was used to measure intestinal Ca absorption, plasma Ca efflux
(pCa-efl) and Ca retention (Ca-ret) in bone after 28 days. All parame-
ters were correlated with the biochemical and histological data. Seven
pts had a high turnover (HTO), 16 a low turnover osteopathy (LTO)
and 20 a mixed type (MUO) of ROD. Pts with LTO had lower serum
PTH levels and lower pCa-eff values (p < 0.001). Ca-ret was low
compared to the MUO and HTO group (19.2 vs 37.1 and 72.2%, re-
spectively). pCa-eff and Ca-ret correlated positively with PTH (r 0.7
and r 0.8, respectively) and histological signs of bone turnover (no
of osteoblasts and -clasts, osteoid volume etc). pCa-eff together with
serum PTH level allowed in 37/43 pts a correct estimation of bone
turnover. Ca-kinetic studies are a valuable tool to examine the distur-
bed Ca metabolism in ROD and may be used in measuring the re-
sponse to treatment. In addition a low pCa-eff and Ca-ret explain the
tendency for the development of hypercalcemia in pts with LTO.
Calcitriol for the treatment of renal osteodystrophy in patients with
mild and moderate chronic renal faillure (CRF). J. Malegos, A. Gera-
kis, Th. Apostolou, G. Metaxatos, Ch. Christodoulidou, M. Giamalis,
M. Siakotos, and A. Billis, Division of Nephrology, Evangelismos Ho-
spital, Athens, Greece. The therapeutic effect of Vit. D in renal osteo-
dystrophy (RO) was prospectively studied in 10 patients (pts) (4 M, 6
F) 38 to 66 years old, with CRF (serum creatinine 2-6 mg%, creatini-
ne clearance 20-50 mI/mm) (Group A) who were treated with calci-
triol 0,25-0,5 sg daily for 12-14 months. As a control group were used
10 pts matched for age, renal function and known duration of CRF
with those of group A. At the beginning and the end of the study pe-
riod, the biochemical and hormonal parameters of RO were measu-
red and bone biopsies were performed in all pts. At the beginning
there were no statistically significant differences in the biochemical,
hormonal and histological findings between the two groups. Histo-
morphometrically, in group A 6 pts had secondary hyperparathyroi-
dism (SHPT), 3 pts mixed bone disease and 1 pt normal bone, while
in group B 6 pts had SHPT, 1 pt mixed bone disease and 1 pt normal
bone. At the end of the study, the pts of group A in relation to those
of the control group, showed an increase in serum calcium and
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25(OH)D3; a fall in their serum parathormone, alkaline phosphatase
and osteocalcin; an increase in the mineralization front; and a decrea-
se in the number of osteoclasts. All these changes were statistically
significant at p 0.05. Histomorphometrically, 7 of the pts who recei-
ved treatment showed SHPT and the remaining 3 normal bone, while
in the control group all pts had lesions of either SHPT (8) or mixed
bone disease (2). The deterioration of renal function was similar in
both groups. In conclusion, in pts with mild and moderate CRF calci-
triol improves the biochemical, hormonal and histological parameters
of RO without undue deterioration of renal function.
The influence of the intravenous administration of hydroxyvitamin
D3 on the renal osteodystrophy of dialyzed patients. A. Triantaphylli-
dou, P. Bekiarides, N. Evangellopoulos, andA.A. Diamantopoulos, Re-
nal Unit, St. Andrews State Hospital and Diagnostic Center "B-
Diagnosis", Patras, Greece. In order to investigate the action of the
intravenous administration of 1-a hydroxyvitamin D3 on renal osteo-
dystrophy due to secondary hyperparathyroidism, we undertook the
present study. Five patients (three males and two females), with an
average age of 55.3 3.1 years, were included in the study. They
were dialyzed in our unit for 12 hours weekly using a couprophan
dialyzer, and with a calcium bath consentration of 1.67 mml/Iiter.
Before starting treatment, we checked the serum levels of calcium,
aluminium, phosphate, alkaline phosphatase and PTH. The bone
density and the calcium bone concentration were examined using the
method of double photon absorbtion. Afterwards 1 jigr of 1 — a hy-
droxivitamin D3 (Leo), was administered intravenously, thrice a
week, at the end of each dialysis session. The treatment lasted for two
months at the end of which all the above mentioned tests were repea-
ted. There was a statistically significant increase (p < 0.01), of the
serum calcium by using the paired t-test. However using the same sta-
tistical method no improvement was found either of the abnormally
high PTH levels, or of the mean bone density and the mean calcium
bone concentration, with the double photon absorbtion method. We
conclude that there was only an improvement of the serum calcium
level, but not any difference of the very sensitive radioisotopic met-
hod, at least when using these very low 1 — a doses.
A comparative study of renal osteodystrophy in patients undergoing
hemodialysis (HD) and continuous ambulatory peritoneal dialysis
(CAPD). Th. Apostolou, A. Gerakis, M. Siakotos, G. Metaxatos, J.
Malegos, N. Nikolopoulou, D. Hadjiyannakos, N. Toupadaki, and A.
Billis, Division of Nephrology, Evangelismos Hospital and Department
of Hygiene and Epidemiology, University of Athens, Greece. The main
parameters of renal osteodystrophy were studied in 28 patients (pts)
undergoing HD and in 18 pts undergoing CAPD. The two groups we-
re comparable in sex, age, known duration of the chronic renal failure
before starting HD or CAPD and duration of dialysis treatment
which was in all pts greater than 12 months, None of the pts had been
submitted to parathyroidectomy or renal transplantation, had been
treated with vitamin D, desferioxamine, steroids or anti-convulsant
drugs, or had changed the initial technique of dialysis. The study pro-
tocol included clinical examination and laboratory assessment of the
pts (biochemical, hormonal, radiological, ultrasound of parathyroids
and bone biopsy), Statistical analysis of the data showed that the pts
undergoing HD, compared to those who were on CAPD, developed
more frequently pruritus (p — 0.04) and radiological findings of secon-
dary hyperparathyroidism (p = 0.03), had higher values of serum Ca
and P (p = 0.05 and 0.04, respectively), and histologically presented a
higher bone nrinositional rate (p = 0.O) and a heavier aluminium de-
position in bone (p — 0.003). Although there was not a statistically
significant difference between the two groups of pts regarding the hi-
stological type of renal osteodystrophy, there was a tendency for the
development of secondary hyperparathyroidism among the pts who
were on HD. In conclusion, our HD pts disclosed more frequently
than those who were on CAPD biochemical, radiological and histolo-
gical findings of secondary hyperparathyroidism along with a heavier
aluminium deposition in bone.
The combination of Hemoperfusion — Hemodialysis (HP-HD) with
use of desferioxamine (DFO) in aluminium (AL) removal. K. Platsakis,
S. Giannakakis, 1. Stavroulakis, A. Koroneos, and N. Papadodimas,
Nephro/ogy Department, Tzan ion General Hospital, Piracus, Greece.
Aluminium accumulation in ESRD patients is responsible for many
clinical symptoms. The limited adequacy of HD for its removal is
well known. Four male HD patients aged 47-70, with treatment dura-
lion 77.7 32.8 months, having the highest initial serum AL levels,
were selected for study. They were infused with lg DFO IV and se-
rum AL levels were measured 44 hours later. A three hour session of
combined HP-HD followed with blood flow 250 mI/mm. Aluminium
clearance of the whole system and each filter separately was measu-
red, at 15' and 180' from the beginning of the session. AL removal
per patient was estimated as well. At 15' clearance of the HP-HD
combination was 107.21 10.85 mI/mm with HP yielding 88.32
12.94 mI/mm and at 180' the total system clearance was 32.99
2.68 ml/min with HP participation 22.63 3.65 mI/mm. AL remo-
val was estimated at 906.5 203.87 pig and its serum levels decrea-
sed from 166.5 17.13 pig/liter to 101.75 5.74 jig/liter. It is conc-
luded that HP-HD combination with use of low doses DFO is safe for
the patients and adequate in AL removal. The efficacy of the system
is reduced significantly during treatment.
Insulin and hypertension in Chronic Renal Failure (CRF). S. Kapou-
la.s, M. Karamouzis*, N. Goutsaridis, A. Sioulis, A. Lazaridis, P. Niko-
laidis, A. Dimitriadou*, and A. Tourkantonis, 1st Dept of Internal Me-
dicine and Laboratory of Biochemistry, Medical School, University of
Thessaloniki, Greece. Chronic renal failure (CRF) is a condition fre-
quently associated with insulin resistance and hyperinsulinemia. In
spite of the fact that insulin plays an important role in the pathogene-
sis of essential hypertension, its role in the hypertension of CRF has
not been elucidated. For this purpose, we performed the oral glucose
tolerance-test (OGTT) and measured the total and ionic serum Ca in
20 normal controls and 40 patients with CRF (20 hypertensives and
20 normotensives) with Ccr 30-10 mI/mm. We calculated the insuli-
nogenic index (1.1.) (insulinlglucose) and the mean value of insulin
(measured at the 5 times of the OGTT). In the control group, the
mean values of insulin in all patients was 4.59 5.56 piU/ml, of the
1.1. 0.420 0.40, of the total Ca 4.59 0.22 and of the ionic Ca 2.28
0.11 mEq/liter. In the normotensives the OGTT was abnormal in 5
out of the 20 patients (2 5%) and the mean values of insulin 49.78
0.68 piU/ml (p — NS), of the 1.1. 0.425 0.040 (p NS), of the total
Ca 4.38 0.15 (p < 0.001) and of the ionic Ca 2.22 0.07 mEq/
liter (p <0.05). In the hypertensive patients, the OGTT was abnor-
mal in 13 out of the 20 patients (6 5%) and the mean values of insulin
were 64.11 10.37 piU/ml(p <0.001), of the 1.1. 0.410 0.069 (p
NS), of the total Ca 3.72 0.13 (p <0.001) and of the ionic Ca 1.69
0.19 mEq/liter (p <0.001). Conclusions: 1) The hypertensive pa-
tients with chronic renal failure have a higher rate of abnormal
OGTT, higher levels of insulin and lower levels of ionic Ca compared
to the normotensive ones. 2) The hyperinsulinemia and insulin resi-
stance observed in chronic renal failure seem to contribute to the pa-
thogenesis of hypertension in patients with CRF.
Insulin and atrial natriuretic peptide (a-ANP) in chronic renal failure
(CRF). S. Kapoulas, M. karamouzis", A. Sioulis, N. Goutsaridis, P.
Kordatos, P. Nikolaidis, A. Dimitriadou*, and A. Tourkantonis, 1st
Dept of Internal Medicine and Laboratory of Biochemistry Medical
School, (Jnjversitv of Thessaloniki, Greece. The atrial natriuretic pep-
tide (a-ANP) is frequently found elevated in the plasma of patients
with CRF. Factors which are implicated in the a-ANP incease are hy-
pervolemia, hypertension, hormonal and, to a less degree, its reduced
secretion and metabolism. Recent studies have shown that there is an
interaction between a-ANP and insulin in their action, secretion and
metabolism. Because CRF is associated with insulin resistance and
hyperinsulinemia, we studied the relationship between a-ANP and
the degree of hyperinsulinemia. We measured the levels of a-ANP,
the mean values of insulin (measured at the 5 times of the oral glucose
tolerance test) and plasma renin in 20 normal controls and 32 pa-
tients with CRF (17 hypertensives and 15 normotensives) with Ccr
40-20 mI/mm. In the control group the mean values of insulin of all
patients was 43.57 6.55 piU/ml, of the a-ANP 45 7 pg/mI and of
the renin 1.45 0.62 rig/mI/hr. In the normotensives, the mean va-
lues of a-ANP was 128.2 37.8 pg/mI (p < 0.001), of the insulin
49.72 7.97 piU/ml (p <0,05) and of the renin 1.01 0.45 ng/ml/
hr (p < 0.05). In the hypertensives the mean values of a-ANP was
169.3 33.18 pg/mI (p < 0.001), of the insulin 69.08 10.87 piU/ml
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(p < 0.001) and of the renin 5.31 1.53 (p <0.001). Conclusions:
1) The hypertensive patients with CRF have higher levels of a-ANP,
insulin and renin compared to the normiotensive ones. 2) The levels
of insulin and a-ANP are positively correlated indepedently of the
Hypertension and there seems to be an interaction between the two
hormonal systems.
Isolated systolic hypertension and renal function: effect of antihyper-
tensive therapy. A.D. Efstratopoulos, M. Meikopoulos, and S. Voyaki,
Hypertension Clinic and 3rd Medical Dept, Athens General Hospital
Athens, Greece. The aim of the present prospective study was to eva-
luate the effect of antihypertensive treatment in renal function of pa-
tients with Isolated Systolic Hypertension (ISH) and normal renal
function. Fifty-eight pts (25M/33F, 54-84 yrs of age) followed in our
Hypertension Clinic, were included in the study; finally 31 of those
patients (1 OM/2 IF, 54-84 yrs old) followed for a period of 6-46
months were evaluable. Evaluation of renal function was done by
GFR measurement (mllmin/l .73 m2) twice in a month, before star-
ting treatment, and under treatment during the last 2 months of the
study period. Blood pressure (BP) before treatment was 170.6 6.4/
75.4 3.5 mmHg (m (range: 160-225/60-90 mmHg), and
under antihypertensive treatment (ACE-inhibitors, Diuretics,
B-blockers, Ca+Lblockers) the final BP was 143.6 5.4/78.3 2.8
(p <0.0l/NS). Twenty-three out of 31 patients (74.2%, group-A)
sustained or improved their renal function during the study period
(iGFR: 10 ml/min/1.73 m2 or increased >10 ml/min/l.73 m2),
while 8 patients (25.8%, group-B) showed a deterioration of renal
function (GFR decreased more than 10 ml/min/ 1.73 m2) under treat-
ment. The age of patients in group-B was significantly smaller than
that of group-A (63.4 7.7 vs 69.9 6.7, p: 0.031), also patients of
group-B were more commonly under treatment with diuretic mono-
therapy, in comparison to the patients of group-A that were more
commonly treated with ACE! (7 8.26%) than those of group-B (50%).
We conclude that: 1) Renal function in patients with ISH may remain
stable or even inproved in 74.2% of the patients, under the effect of
antihypertensive treatment (especially with the use of ACE!), and 2)
2 5.8% of the patients showed a deterioration of renal function (even
with "normal" serum creatinine values), especially under chronic diu-
retic monotherapy.
Satisfactory long-term blood pressure control of renovascular hyper-
tension (RVH) following successful percutaneous transluminal angio-
plasty (PTA). I.G. Viachojannis, P. Kurz, D. V. Vlahakos, E. Hinari, P.
Grutzmacker, and W. Schoeppe, Division of Nephrology, Patras Uni-
versity Hospital, Rio, Patras, Greece and II Med. Klinik, St Markus
Krhs. und GSF, Frankfurt, Germany. PTA revolutionized the aetiolo-
gic therapy of RVH in both fibromuscular dysplasia (FMD) and athe-
rosclerotic disease (ASD). Although the immediate post-dilatation ef-
fect on arterial Blood Pressure (BP) is well documented, the long term
benefit is not yet, so clearly shown. In the present communication, we
analyzed data of 124 successive PTA in patients with RVH (90 with
ASD and 34 with FMD). The following table shows the systolic and
diastolic blood pressures (mmHg), as well as, the mean number (No)
of antihypertensive medications before, immediately after and 3
months, 1 year and three years following PTA.
Before After 3 months 1 year 3 years
FMD n34 n34 n30 n29 n17
systBP 153±19 131±4 131 17 134±17 137±20
diast BP 95 12 84 9 83 9 83 10 84 8
No meds 1.70 0.65 0.63 0.79 0.80
ASD n90 n=90 n69 n=57 n=25
syst BP 162 22 145 16 145 18 146 17 144 15
diast BP 91 14 84 9 80 8 85 8 86 8
No meds 2.53 1.48 1.55 1.38 1.36
PTA resulted in normalization of BP in 59% of patients with FMD, as
opposed to 26% of those with ASD. Restenosis was seen in 24% of
patients with FMD and in 19% of patients with ASD, one year follo-
wing successful dilatation. In conclusion, with the exception of reste-
nosis within the first post-dilatation year in a subset of patients with
RVH treated with PTA, the majority of those patients can be expec-
ted to have satisfactory long-term BP control without other therapy or
with a small number of antihypertensive medications.
Erythropoietin improves "functional anaemia" in predialysis chronic
renal failure children. F. Comianou1, I. Papassotiriou2, A. Karaklis2,
and H. Georgaki-Angelaki', 1Dept. of Pediatric Nephrology and 2Hae-
matology Laboratory, "Aghia Sophia" Children's Hospital, Athens,
Greece. The anaemia seen in children with chronic renal failure
(CRF) is multifactorial and characterized by decreased peripheral
oxygen delivery and low circulating erythropoietin level. The aim of
this study was to investigate the effect of r-HuEPO on the level of
haemoglobin (Hb), 2,3 Diphosphoglycerate (2,3 DPG), oxygen affini-
ty (P50), qygen carrying capacity (O) and oxygen released to the
tissues (02) in 6 predialysis children with CRF (GRF with Cr5-
EDTA: 12.3 7.2 ml/min/1.73 m2). The measurements were perfor-
med before (I) and three months after (11) treatment with r-HuEPO in
a dose of 50-100 U/kg, thrice weekly. The results (mean SD) are
shown in the table.
Hb MCV 2,3DPG P50 O O
g/dl fi sm/ml RC mmHg vol % vol %
1 6.8 0.8 82.6±4.5 6.13±0.15 30.7±0.6 9.1 1.0 2.8±0.2
11 10.2±1.7 88.7±5.2 5.65±0.14 30.2±0.5 13.9±2.4 4.1±0.6
The pre-treatment with r-HuEPO results shown reduced 0 due to
low levels of Hb and inappropriate to the degree of anaemia 2,3DPG
and P50 values (expected 6.50 tm/ml RC and 32.5 mmHg respective-
ly). Oxygen release increased significantly post-treatment due to the
increase of Hb levels, while the 2,3DPG level is now significant lower
and appropriate to the degree of anaemia. The P50 value remained
unchanged. All the above indicate that treatment with r-HuEPO im-
proves "functional anaemia" in predialysis CRF children.
Combined iv iron and low dose erythropoietin (rHuEPO) therapy in
HD-patients. T. Tsobanelis, P. Kurz, D. Hoppe, J. Vlachojannis*, and
P. Grlltzmacker, II. Med. Clinic, St. Markus Hospital, Frankfurt/M,
FRG, *Dept of Nephrology, Patras University, Greece. Development
of iron deficiency has been observed during rHuEPO therapy, pre-
venting from adequate therapeutic success. We investigated: 1. The
incidence of functional iron deficiency during low dose i.v. rHuEPO
combined with i.v. iron therapy, 3. Tolerance of this regimen. Forty
HD-pts. without iron deficiency [Hct < 26%, ferritin >150 kg/liter,
transferrin saturation (TFsat) >20%], were treated with i.v. rHuEPO
(3 x 20 U/kgr body wt). Blood cell counts were controlled weekly and
iron status twice monthly. Iron was given i.v. when TFsat was <20%
(3 x 40 mg Fe3 — Na gluconate/week, after HD). Results: 32/40
(80%) pts developed iron deficiency before reaching the target Hct(30-35%). 19/40 (47.5%) pts reached the target Hct within 6 weeks.
Despite intensive i.v. iron substitution TFsat remained low without a
fall of ferritin. After 12 weeks, all 40 pts. had reached the target Hct,
including 8 pts where rHuEPO was increased to 3 x 40 U/kgr body wt
(iHct <3% after 6 weeks). Under combined i.v. iron and rHuEPO
therapy hct increased by 0.8%/week. Conclusions: 1) Even under low
doses rHuEPO functional iron deficiency developed in 80% of the
pts. 2) Storage iron pool was not adequately mobilized, 3) Under
combined i.v. iron and rHuEPO an improved response to rHuEPO
was accomplished without major side effects.
Improvement of brain cell function after correction of renal anemia
with erythropoietin (EPO) in CAPD patients. I.G. Viachojannis, G.
Perschon, D. V. Viahakos, E. Hinari, P. Grutzmacher, and W. Schoep-
pe, Division of Nephrology, Patras University Hospital, Rio, Patras,
Greece and liMed. Klinik, St. Markus Krhs. und GSF, Frankfurt, Ger-
many. Metabolic encephalopathy, as part of the uremic syndrome,
has been long recognized and pathologic tracings have been observed
on conventional EEG recordings. The newest method of Topographic
Brain Mapping (TBM) utilizes computer analysis of multiple EEG re-
cordings and makes possible to define subtle neurophysiology chan-
ges in brain cell function and localize their topographic distribution
in the brain. In order to dissociate the effect of anemia from the effect
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of "uremic toxins" on uremic encephalopathy, we studied TBM re-
cordings in 10 patients on CAPD, before and after correction of renal
anemia with EPO. Patients were given EPO 20 lU/Kg SQ thrice wee-
kly and their hematocrits improved from 25 2.2 % to 35.2 2.3
%. TBM recordings were evaluated with respect of frequency, absolu-
te power and topographic distribution after the following evoked po-
tentials: sensorimotor (SEP), visual (VEP) and acoustic (AEP). Chan-
ges in VEP were not significant in any patients. By contrast, improve-
ment of SEP was found in 8 patients and of AEP in 3. We conclude
that uremic metabolic encephalopathy is at least partly reversible af-
ter correction of renal anemia with EPO.
Study of endocrine function in patients under haemodialysis during
therapy with erythropoietin. D. Tsakiris, G. Visvardis, D. Papadopou-
lou, and M. Papadimitriou, Department of Nephrology, Hippokration
General Hospital, Aristotelian University of Thessaloniki, Greece. The
aim of the study was to evaluate the possible hormonal changes in
patients under chronic haemodialysis (HD) before and after treat-
ment of anaemia with recombinant human erythropoietin (EPO). We
studied six patients (3 males) with a mean age of 45 years (range 33-
60) and a mean duration of HD of 65 months (range 34-137). The
basal levels of anterior pituitary hormones (LH, FSH, TSH, prolac-
tin), thyroid hormones (T3,T4) and testosteron were measured. Mo-
reover, the differences in LH and FSH levels following stimulation of
LHRH (LHRH-test) and in TSH and prolactin levels following stimu-
lation of TRH (TRH-test) were accessed both before and after achie-
vement of the therapeutic goal (Hct 30-35%). The mean duration of
treatment was 128.5 8.2 days and during this period haematocrit
increased from 19 4.3% to 32.8 4.3% (p <0.01). Six normal
subjects matched for age and sex were used as controls. A statistical
significant difference in T3,T4,LH and prolactin levels before treat-
ment was observed in patients compared to controls (p < 0.002, p <
0.01, p <0.02 and p < 0.008 respectively). In contrast, no significant
changes in hormone levels were observed before and after treatment
with EPO, although in 4 of the 6 patients an improvement of libido
was observed. In conclusion no alterations in studied hormone levels
were observed. The improvement of libido was probably due to the
correction of anaemia which resulted in increased physical well being
and improved cellular metabolism.
Isotopic study of anemic patients under hemodialysis before and after
treatment with erythrupuietin (EPO). D. Tsakiris, D. Papadopoulou, A.
Siountas, G. Lagaza/is, N. Karatzas, and M. Papadimitriou, Depart-
ment of Nephrology, Hippokration General Hospital, Aristotelian Uni-
versity of Thessaloniki, Greece. Total body hematocrit (TBHct), red
cells survival (T) and plasma volume (PY), blood volume (BY) and
red cells volume (RCV) per body surface (5), were estimated by isoto-
pic methods in 15 anemic patients (5 men, mean age 46.4 years) on
hemodialysis (HD) before and after intravenous administration of re-
combinant human erythropoietin (EPO) in order to treat anemia
(therapeutic target: Hct = 30-35%). The aim of the study was to com-
pare the changes of these parameters between patients with and wit-
hout development or exacerbation of hypertension as a side-effect of
treatment (group A, n 8 and group B, n 7 respectively). After a
mean time of 166 55 days and a mean dose of 214 75 IU/kgr
body wt/week, Hct and TBHct increased from 24.5 3.4 and 20.8
3.1 to 36.0 5.7 and 30.6 5.3 respectively (p < 0.001), RCV/S
increased and PV/S decreased from 511 95 and 1965 381 to 774
158 and 1763 304 (p < 0.001 and p < 0.01 respectively), whe-
reas BY/S and T remained stable. Similar changes were observed in
groups A and B, but comparison between these two groups did not
show any changes before and after treatment, neither there was any
difference in the mean dose of EPO or duration of treatment. In conc-
lusion recovery of anemia in HD patients in accompanied by an in-
crease in TBHct and RCV/S and a decrease in PV/S in both groups,
which probably shows that hypertension as a side-effect of EPO, is
not volume-dependent.
Study of cell mediated immunity in hemodialysed patients (HDP) af-
ter administration of l-glycosylated erythropoietin (p-EPO). Chr. ía-
trou', G. Topakas2, D. Skoumi2, N. Afentakis1, E. Karchilaki2, G.
Moustakas', A. Germenis2, A. Stavropoulou2, and P. Zirogiannist,
'Dept. of Nephrology, General Hospital of Athens. 2Histocompatibility
Laboratory, General Hospital of Athens, Greece. Disturbances in cell
mediated immunity (CMI) in uremia usually dominates of the other
immunological disorders. The effect of EPO on CMI has not been
elucidated. The purpose of this work was to study the influence of
f-EPO on CMI in HDP. In 8 HDP, the lymphocytes subsets (Total T:
CD3, Helper: CD4, Suppressor: CD8) and the Natural killer cells
(CD 16) were measured in blood samples, before and 6 months after
the treatment with -EPO, by using flow cytometry. In the same
group of patients and in 8 healthy volunteers (as controls C) we also
studied the T-lymphocyte proliferation after incubation with H3 * and
stimulation by PHA and their suppression by methylprednisolone
(MP). Our results are shown in the tables I and II.
Table I
13 14 T8 T4/T8 KC
Before lI-EPO 966 410 611 221 384 194 1.7 0.35 168 76
After p-EPO 1172 809 723 489 470 317 1.7 0.7 118 79
p p>0.l p>0.l p>0.l p>O.l p>O.l
Table II
PHA cmp MP cpm
I Controls 38281 3270
II Before t3-EPO 12201 6953
HI After f3-EPO 15654 5928
The statistical PHA111 p < 0.001
correlation shows: PHA1_111 p < 0.001
PHA11111 p > 0.1
24750 2964
4497 1692
9182 4789
MP1.11 p < 0.001
MP1111 p < 0.001
MP11...111 p < 0.05
In conclusion, it seems that I-EPO does not improve significantly the
CMI of HDP.
The influence of -gIycosylated erythropoietin (Il-EPO) on platelet
aggregation in hemodialysed patients (HDP). Chr. Iatrou1, A. Kefa-
las3, N. Afentakis', I. Apthentopoulos', S. Antonopoulou2, KA. Demo-
poulos2, R. Stathopoulou3, and P. Zirogiannis1, 'Dept. of Nephrology,
General Hospital of Athens, 2Dept. of Chemistry, Univ. of Athens.
3Dept. of Hematology General Hospital of Children "P. and A. Kiria-
kou'c Athens, Greece. Clinical studies have demonstrated the efficacy
of EPO in correcting anaemia and platelet function in HD pts. Some
of these studies refer to the influence of a-glycosylated EPO on the
platelet aggregation induced by ADP and arachidonic acid (AA). The
purpose of this work is to study the platelet aggregation which is indu-
ced in all three ways ADP, AA and Platelet-Activating Factor (PAF)
after treatment with 3-EPO. In 6 HD pts the platelet aggregation in-
duced by ADP, PAF and AA before and about 6 months after treat-
ment with 3-EPO was studied. Our results show that EC5O (the con-
centration of the substance which gives aggregation to 50% of plate.
lets) for PAF and ADP before and after treatment with Il-EPO are:
PAF EC5O before: 4.13 x 1 0 2.49 x I 05, PAF EC5O after: 2.89 xl0- 1.53 x l0, ADP EC5O before: 2.15 x i0 0.88 x i0-,
ADP EC5O after: 1.92 x l0- 0.49 x (p> 0.1 respectively).
There is not a statistically significant difference in the platelet aggre-
gation induced by AA. In conclusion: I) although I-EPO improves
the platelet aggregation induced in these three ways (ADP, PAF and
AA) its influence isn't statistically significant. The latter may be be-
cause of the small number of HDP included in this study.
Results in 505 renal transplantations. A. Kostakis, Gr. Vosnides, St.
Kyriakides, Sp. Garbis, G. Zavos, I. Boletis, Ch. Stathakis, D. Stama-
tiades, A. Lagouranis, A. Stavropoulos, V. Hatziconstantinou, L. Dou-
,nas, M. Pappas, N. Papadodimas, C. Siamopoulos, and A. Billis, De-
partment of Transplantation and Nephrology. Laikon General Hospi-
tal Athens, Greece. From March '71 - December '91 we performed
505 kidney transplantations. The results of the first 165 transplants,
in which either the conventional or the double (MP + CYA) immuno-
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suppressive therapy were used, have been previously reported. In the
remaining 340 transplants, 189 from living related (Group I) and 151
from cadaveric (Group H) donors, performed between Sept '86 -
Dec '91, triple immunosuppressive regimen consisting of MP +AZA+
CYA was used. There were 10 deaths and 19 graft losses in Group I
and 11 deaths and 18 graft losses in Group II. The remaining 282 pts
are alive with adequate graft function. In Group 1, at 1,3 and 5 yrs the
graft survival rate is 89.6%, 80.3% and 80.3% and the pts survival rate
is 97.0%, 92.5% and 92.5% respectively. In Group II, at 1,3 and 5 yrs
the graft survival rate is 8 1.5%, 77.6% and 66.1% and the pts survival
rate is 93.0%, 90.4% and 87.1% respectively. It is concluded that the
reduced incidence of rejection and infections, the low dose of immu-
nosuppressive drugs and the favourable effect on pt and graft survival
render the use of the triple immunosuppressive therapy in renal trans-
plantation advantageous.
Antilymphocyte globulin (ALG) in renal transplant (RT) patients
with delayed graft function (DGF). Gr. Vosnides, .1. Boletis, D. Slama-
tiadjs, E. Papastathi, E. Psimenou, Ch. Koronis, D. Goumenos, J. Bo-
kos, and A. Kostakis, Department of Nephrology and Transplant Unit,
Laikon General Hospital, Athens, Greece. DGF is a major problem in
RT. The purpose of this study was the comparative evaluation of two
induction immunosuppressive therapies, in pts with DGF due to acu-
te tubular necrosis (ATN). Thirty three cadaveric recipients who pre-
sented post-transplant ATN and received as initial immunosuppressi-
ve therapy methylprednizolone (MP) and azathioprine (AZA) (group
A, N = 17) or ATG, MP and AZA (group B, N 16), were studied.
When graft function improved, CsA was added to maintenance thera-
py. Although there was a significant difference (p = 0.007) in follow-
up time between the two groups (group A 10.7 6.5 and group B 5.3
3.7 months) there were no differences regarding sex, age and HLA
A, B and DR donor/recipient compatibility. No significant difference
was found between the two groups regarding the first 10 post-
transplant months with respect to pt (84.7% vs 88.9%, p = 0.87) and
graft survival (82% vs 87%, p 0.72), creatinine (1.9 0.9 vs 1.6
0.3 mg%, p 0.24), deaths due to infections (one in each group),
CMV infection episodes (3 and 2 respectively) and the number of in-
fection episodes during the first 6 post-transplant months (15 and 20
respectively). It was observed that the pts in group B who received
ATG compared to those of group A, suffered significantly less acute
rejection episodes (4 vs 11, p 0.008), had shorter mean hospitaliza-
tion time (27.6 14.1 vs 39.1 16.8 days, p 0.04), required less
hemodialysis sessions (4.4 5.9 vs 10.7 11.5, p = 0.05) and recei-
ved less corticosteroids during the first month (2.6 1.9 vs 3.8 1.6
gr, p 0.02). It is concluded that in pts with cadaveric RT and ATN,
the addition of ATG to conventional immunosuppressive therapy is
safe and offers the advantage of reduced acute rejection episodes with
less corticosteroid administration and earlier recovery of graft func-
tion without increased morbidity and mortality.
Follow-up of cytotoxic antibodies in haemodialysis (HD) patients du-
ring a 5-years period. D. Tsakiris, P. Vakianis, K. Karamitsos, D. Pa-
padopoulou, D. Memmos, G. Sakellariou, A. Polymenidis, and M. Pa-
padimitriou, Department of Nephrology, Aristotelian University, Hip-
pokration General Hospital, Thessaloniki, Greece. From 1986-1990
the titers of serum panel reactive antibodies (PRA), in 97 HD pa-
tients (65 males, mean age 50 yrs) were evaluated. The aim of the
study was to define the hypersensitized patients and possible factors
contributing to the maintenance of high PRA. During the first year of
the study, 58 pts (60%) had a peak PRA 0-20% (group A), 20 pts
(21%) had PRA 21-50% (group B) and the remaining 19 pts (19%) had
been hypersensitized with PRA >50% (group C). Group C included
more females than group A (47% vs 29%, NS), had more pregnancies
(3.1 vs 2.1, NS), more patients had been transplanted (63% vs 31%,
NS) and had more blood transfusions (42.1 36.7 vs 9.7 11.6, p
< 0.001). After 5 years a shift of patients to the groups with lower
PRA was observed, group A 79 pts (8 1%), group B = 11 pts (11%)
and group C = 7 pts (8%). This change compared to background was
statistically significant (p < 0.01) and was mainly due to the use of
erythropoietin (EPO), which was given to 11/58 (19%), 5/20 (25%)
and 9/19(47%) patients of groups A,B and C respectively (DF 2, x2
=6.035, p <0.05). Six of the 19 initially hypersensitized patients had
stable PRA >50% during the five years of the study, while 4 from the
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remaining 13 patients who changed into groups A and B were trans-
planted (3 successful). In conclusion, a 5-years follow-up of PRA in
HD pts has shown a significant decrease of the proportion of patients
with high PRA. This was mainly due to EPO administration which
limited the need for BT and resulted in transplantation of some hy-
persensitized patients.
Clinical and laboratory findings in lower gastrointestinal track
(LGIT) perforations following renal transplantation (Tx). D. V. Vlaha-
kos, I.G. Vlachojannis, E. Mi/ford, and N. Tilney, Division of Nephro-
logy, Patra University Hospital, Rio, Greece, and Brigham and Wo-
men's Hospital (BWH), Harvard University Medical School, Boston,
USA. LGIT perforations following renal Tx are rare but extremely
serious and frequently lethal: of 1285 renal Tx performed at BWH
between 1951-90, 29 pts (2.2%) developed 32 incidents of LGIT per-
forations, 12 of which (4 1%) were fatal. Rectosigmoid was the site of
perforation in 2/3 of the cases (most frequently due to diverticulitis)
and cecum/ascending colon in 1/4 of the cases (most frequently due to
ischemic enterocolitis). Among >30 clinical and laboratory parame-
ters analyzed, the intensity of immunosuppression with steroids, the
nutritional status and the prompt diagnosis and surgical management
were found to influence most the genesis and the prognosis of perfo-
rations in these pts. Potent immunosuppression is given to maintain
the graft and compat rejection. Following Tx 28% of LGIT perfora-
tions occured within the 1st month, 47% within the first 3 months
and 60% within the 1st year. Similarly, 25% of LGIT perforations
were seen within one week and 50% within a month following Solu-
Medrol pulse therapy for rejection. The intensity of immunosuppres-
sion with steroids, had a grave effect on mortality: the mean daily
dose of prednisone was 3 times higher in those who died (168 65
mg/day), as opposed to those who survived (55 15 mg/day) the
perforation episode (p = 0.02). Also, due to steroids, clinical manife-
stations of perforation at presentation were subtle: 91% of pts were
febrile but only 53% developed fever > 38 C; 84% complained of ab-
dominal discomfort but pain became generalized with rebound ten-
derness and absent bowel sounds in 20%; 31% had nausea/vomiting;
23% diarrhea, 31% constipation and 33% blood in stools. Leukocyto-
sis was seen in only 60% and pneumoperitoneum in 25%. Prompt
diagnosis and surgical intervention influenced the prognosis: 22% of
those operated within 24h of symptoms died as compared to 47% of
those in whom surgical intervention was delayed. Finally, the nutri-
tional status was an important predictive factor for survival: the se-
rum albumin of those who died was 2.5 0.18 g/dl, and those who
survived 3.4 0.15 g/dl (p = 0.002). In conclusion, high index of
suspicion and aggressive diagnostic evaluation, including laparotomy,judicious use of steroids and early nutritional support constitute the
therapeutic targets in LGIT perforations following renal Tx.
Hormonal und ultrasound characteristics of menstrual function after
successful renal transplantation. D. Koutsikos1, A. Sarandakou2, D.
Kassanos2, D. Rizos2, A. Kapetanaki', B. Agroyannis', and!. Phocas2,
'Clinic of Nephrology, 22nd Clinic of Gynecology and Obstetrics, Uni-
versity of Athens, Aretaieio Hospital, Athens, Greece. The cycles of 11
renal transplant recipients (RTR), at least 24 months after stabiliza-
tion of graft function meanstruating regularly, were evaluated by con-
current and systematic determinations throughout the cycle of LH,
FSH, estradiol, progesterone, testosterone, prolactin and SHBG and
by ultrasound follow-up. Biphasic estradiol secretion, midcycle LH
and FSH surge, duration of luteal phase, midluteal progesterone va-
lues and ultrasonic parameters were consistent with: 1) normal ovula-
tory cycles in five women, 2) ovulatory cycles with luteal phase defi-
ciency in five women and 3) anovulatory cycles in one woman. Thus,
after successful renal transplantation, luteal phase deficiency was a
very common syndrome, in equal percentage with normal ovulatory
cycles.
Effect of calcium antagonists on renal graft function. P. Alivanis, D.
Grekas, A. Siulis, C. Diudis, V. Derveniotis, S. Vasiliu, and A. Tour-
kantonis, Renal Unit, First Medical Department, University Hospital
AHEPA, Thessaloniki, Greece. Studies in experimental models of re-
nal ischemia have shown that calcium antagonists are effective in the
protection of the ischemic insult. Thirty-five patients who received a
kidney graft the last two years (nifedipine group) were compared with
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35 consecutively transplanted patients (control group), The two
groups were compatible for age, sex, duration of hemodialysis, graft
matching and total number of blood units transfusion. The patients
of the nife&2ine group were given 0.2 mg nifedipine (solution 10%)
through the renal artery immediately after revascularization and also
nifedipine per os during all the study period. Adequate diuresis (1
mI/mm) was obtained in 14.5 37,2 and 43.9 46.8 hours after
transplantation in nifedipine and control group respectively (p <
0.01). Acute tubular disfunction frequency and serum creatinine le-
vels were found higher in the control group. Fractional excretion of
sodium was not found to be different in the two groups the first day,
but it was significantly lower the first week after transplantation in
the nifedipine group (p < 0.05). Acute rejection episodes were found
to be more frequent in the control group the first six months after
transplantation (p < 0.05). It is suggested that nifedipine is effective
in the protection of renal function after transplantation.
Infections in renal transplant (RT) patients treated with triple iminu-
nosuppressive therapy. J. Boltis, Ch. Stathakis, Ch. Koronis, E. Psi-
menou, E. Papastathi, D. Stamatiadis, D. (loumenos, G. Zavos, A. Ko-
stakis, and Gr. Vosnides, Department of. 'Iephrology and Transplant
Unit, Laikon General Hospital, Athens, (reece. The purpose of the
study was the evaluation of the incidenc and type of infections, as
well as their clinical implications, in RT pt treated with triple immu-
nosuppressive therapy (Methylprednisolone, Azathioprine and Cyclo-
sporine). We evaluated retrospectively, the infection episodes in 84
pts (53 males, 31 females), aped 40.2 12.7 years, who underwent
RT (42 from cadaveric and 42 from living related donor) from Aug.
89 until Aug. 90 and were under triple immunosuppressive therapy.
During the 15.3 6.7 months of follow up we noted: 1) Five deaths,
from which only one was due to infection, 2) Ten renal graft losses,
from which only one was due to infection, 3) One hundred and four
infection episodes in 57 (67%) pts (acute pyelonephritis: 33%, asymp-
tomatic bacteriouria: 19%, CMV: 14%, pulmonary infection: 10%,
upper respiratory infection: 9%, HSV: 5% and others: 10%), Sixty se-
ven percent of the infection episodes occured during the first 6 post-
transplant months. 4) Thirty pts (53%) experienced only one infection
episode while 27 pts (47%) had multiple ones. No significant differen-
ces were observed between pts with and those without infection regar-
ding sex, age, graft source, follow-up time, number of acute rejection
episodes, total steroid dose, as well as Pt and graft survival. Our fin-
dings indicate, that triple immunosuppressive therapy in RT is safe
regarding the incidence of infections and infection complications.
Hepatis C virus (HCV) infection in renal transplant patients. J. Bole-
us, Ch. Siathakis, E. Papastathi, D. Goumenos, D. Stamatiadis, E. Va-
fiadi, A. Chatzakis, A. Kostakis, and Gr. Vosnides, Department of
Nephrology and Transplant Unit, Laikon General Hospital, Athens,
Greece. The purpose of the present study was the utilization of the
2nd generation immunoenzymic test for the evaluation of the preva-
lence and clinical implications of HCV infection in renal transplant
(RT) pts. For this, the presence of anti-HCV was determined by using
the "Abbott HCV ELA 2nd Gen./anti-HCV EIA suppl, assay" in 156
RT pts (99 M, 57 F) aged 42.6 11.8 yrs who were on HD prior to
RT for 2.5 2.0 yrs and with functioning graft for 37.1 29.7
months. Anti-HCV were present in 41/156 pts (26.3%) and their pre-
valence was not related to the sex (p — 0.92) or the age (p 0.14) of
the RT pts, The anti-HCV (+) pts compared to the anti-HCV (—) pts
had significantly shorter time with functioning graft (29.5 22.5 vs
39.9 31.7 months, p 0.03) and longer pre-transpiant time on HD
(3.2 2.3 vs 2.3 1.9 yrs, p = 0.04). The 41 anti-HCV (+) pts were
found to be: 1 (2.4%) HBsAg (+), 21(51.2%) anti-HBc (+), 23 (56%)
anti-I-lBs (+) and 15 (36.6%) anti-HBs (+)/anti-HBc (+). Twenty-three
of the 41(56%) anti-HCV (+) RT pts had persistently abnormal liver
function tests (LFT'S). The prevalence of abnormal LFT'S was not
significantly different (p 0.36) from that of the anti-HCV (—)/HBsAg
(+) RT pts. The results of the present study indicate that: 1) In RT pts
the prevalence of HCV infection is high and proportional to the pre-
transplant HD time and inversely proportional to the post-transplant
time. 2) In a substantial proportion of anti-HCV (+) RT there is evi-
dence of previous infection with hepatitis B virus. 3) Anti-HCV (+)
RT pts have a high prevalence of abnormal LFTS comparable to that
of the HB5Ag (+) RT pts.
Evaluation of morphological changes of peritoneal membrane in
CAPD patients with loss of ultrafiltration. V. Vargemezis, .1. Hatzibou-
gias, R. Papadakis, A. Euthimiadou, E. Thodis, and N. Liranlzopou-
los, Division of Nephrology, Thrace University, Greece. In order to
evaluate the morphological status of peritoneum in CAPD patients
with ultrafiltration loss, we performed open biopsies of peritoneal
membrane in 10 such pts. Specimens of parietal peritoneum were exa-
mined with light and electron microscopy. The observed changes in
all pts were moderate to severe fibrosis of parietal peritoneum and
severe oedema of submesothelial connective tissue. In 8 pts we noti-
ced the presence of numerous particles of foreign body material infil-
trating all strata of peritoneum. These foreign bodies were of various
shapes and dimensions with and without cellular reaction (Histiocy-
stic) around them. Using electron scanning microscopy with Röent-
gen microanalysis technique, it was revealed that the nature of these
particles was a complex of anorganic substances composed of pieces
of silicone, titanium, P and Conclusions: I) We confirm
the severe structural changes of peritoneum (thickening, fibrosis etc.)
reported in the literature in CAPD patients with ultrafiltration loss or
diminution. 2) Foreign body particles could play an important role in
the pathogenesis of these changes.
Evaluation of CNS-functlon in CAPD patients using magneto-
ecgephalography (MEG). Comparison with hemodialysis patients. E.
Thodis, P. Pasadakis, and V. Vargemezis, Division of Nephrology,
Thrace University, Greece. In order to evaluate the CNS-function of
uremic patients, the magnetic activity emmited from the brain of 20
pts (10 pts on CAPD and 10 on HD) was measurçd. MEG consisted
of taking 32 concecutive records from the 32 equally spaced points
chosen on the uremic scull around our reference points T3, T4 of the
international 10-20 electrode placement point system. MEG data we-
re converted using an AD-converter with sampling frequency 256 Hz
and stored in a P/C. Our results showed significant differences be-
tween the two groups. In all HD-patients there was an abnormal ma-
gnetic brain activity with high spectral amplitudes (in the band 2-7
Hz) which was more prominent in pts on hemodialysis for more than
4 years. The magnetic activity was whithin normal ranges in all
CAPD pts. According to these observations we conclude that: 1) The-
re is a high magnetic brain activity in HD-pts, which, in accordance
with the EEG findings are signs of diffuse encephalopathy. 2) CAPD
pts show a very low magnetic brain activity which must be interpret-
ted as normal brain function and 3) MEG can be useful in further
measurment of adequacy of dialysis.
Metabolic disturbances in CAPD and platelet prostanoids produc-
tion. S. Anton iou, A. Dimitriadis, and P. Makris, CAPD Unit, Agios
Dimitrios Hospital, Thromb. Hemost. Unit, AXEPA Hospital, Thes-
aloniki, Greece. Metabolic disturbances in CAPD tend to be similar
to those observed in nephrotic syndrome and diabetes mellitus, con-
ditions with overt platelet hyperactivity. A similar platelet behaviour
in CAPD could be expected. The metabolic activity of the cyclooxy-
genase pathway (COP) was studied in platelets of 20 patients on
CAPD and 13 individuals (C). COP was evaluated by determining
malonyldialdehyde production — which reflects TXA2 production —
under basal (MDA) and stimulated (MDAa) conditions using the
thiobarbituric method and N-ethylmaleimide as stimulator. In
CAPD, MDA (nmol/10 9 plat) was higher than C (1.89 0.89 vs
1.32 0.45, p < 0.05). MDA was similar (6.26 1.54 vs 6.66
1.63) but the % was less in CAPD (387 163 vs 540 172, p <
0.02). CAPD patients had significantly higher levels of glucose (G),
triglycerides (Tg) and fibrinogen (F) and lower HDL and albumin
(Alb). A correlation of MDA with G (r — 0.507, p < 0.05) and Aib (r —
—0.456, p < 0.05) was found. In CAPD, platelets have a tendency to
increase prostanoids production under basal conditions (because of
hyperglycemia and hypoalbuminemia) while they appear exhausted
under stimulated conditions.
Epidemiology of peritonitis and sensitivity/resistance of microorga-
nisms during a five-year period of CAPD in one center. D. Tsakiris, P.
Vakianis, G. Visvardis, P. Tsatrafillias, R. Antoniadou, A. Kyrou, and
M. Papadimitriou, Department of Nephrology and Microbiology, Hip-
pokration General Hospital, Thessaloniki, Greece. From 1987 to
1991, 552 cultures of peritoneal dialysate in patients on CAPD were
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performed and the sensitivity of microorganisms to antibiotics was
studied, in order to evaluate the epidemics of peritonitis and the pro-
bable development of resistance to chemotherapy. Gram(+) microor-
ganisms were isolated from 243 cultures (44%), Gram(—) from 97
(18%) and fungi from 59 (11%). In 5 cultures (1%) more than one
pathogen were developed and 148 cultures were negative (26%). This
proportion remained stable during the study and ranged from 40% to
53%, 9% to 26%, 7% to 15% and 15% to 38% respectively. The most
common microorganisms were staph. epidermidis in 127/552 (2 3%),
staph. aureus in 81/552 (15%), pseudomonas species in 31/552 (6%)
and E.Coli in 30/552 (5%). Excluding negative cultures and those in
which fungi were isolated, the sensitivity of 340 cultures to vancomy-
cm (V), ceforanide (C), netromycine (N), amikacin (A) and trimetho-
prime-sulfamethoxazole (T/S) was studied. Only the first four anti-
biotics were widely used in the treatment of peritonitis. The overall
sensitivity of Gram(+) and (—) microorganisms was 81%, 77%, 73%,
79% and 58% to V, C, A, N and T/S respectively. Gram(+) microorga-
nisms were sensitive to V, N, A, C, and T/S in 82%, 81%, 79%, and
52% respectively. The sensitivity to V and C remained stable during
the study, whereas resistance to N, A and T/S developed after three
years. The sensitivity of Gram(—) microorganisms to N, A, V, C and
T/S was 77%, 76%, 73%, 69%, and 44% respectively. The sensitivity
to N remained stable during the study ranging from 75 to 84%, whe-
reas the sensitivity to A, V, C and T/S ranged from 54% to 100%, 57%
to 81%, 42% to 88% and 19% to 84% respectively. In conclusion,
Gram(+) microorganisms and especially staph. epidermidis and
staph. aureus were the main pathogens of peritonitis during a five-
year CAPD period. The sensitivity of both Gram(+) and Gram(—)
bacteria to V, N and A remained stable, justifying the use of these
antibiotics as a first choise agents in the treatment of peritonitis.
Reevaluation of peritonitis due to staphylococcus epidermidis (SE) in
CAPD. A. Katirizoglou, N. Apostolidis, E. Prassa, G. Bougatsos, and
T. Mountokalakis, 2nd Department of Internal Medicine, University of
Athens, Medical School, Hippokration Hospital, Athens, Greece. The
importance of peritonitis as a restrictive factor in the advance of
CAPD is well recognized. Most studies, however, deal with the mana-
gement and prevention of peritonitis due to causes generally accepted
as hard to treat and disregard bacterial pathogens presumed to cause
mild forms of peritonitis. Although SE is considered to cause a mild
and easily managed peritonitis sporadic studies have challenged this
view. During the period 1982-1991, 178 episodes of peritonitis in 115
patients undergoing CAPD were observed in our unit. In 36 (20.2%)
of these cases SE was demonstrated to be the causative agent. In all
cases, fever was present and more than 4.000 cells per ml were coun-
ted in the first sample of peritoneal fluids. In 8 cases, the clinical pic-
ture was severe mimicking acute abdomen (acute, diffuse abdominal
pain, abdominal wall rigidity, nausea, vomiting). In two additional
cases there were recurrences of peritonitis and in one of them remo-
val of peritoneal catheter was judged to be necessary. Recurrences we-
re attributed to non compliance to the long term therapeutic regimen
used in our unit. This regimen includes intraperitoneal administra-
tion of two antimicrobial agents for at least 21 days after the first
negative culture. It is concluded that the view that peritonitis due to
SE has a mild and uncomplicated course should be reconsidered.
Therapeutic management of exit-site and/or subcutaneous tunnel in-
fections in patients undergoing CAPD. G. Metaxatos, B. Margellos, N.
Nikolopoulou, D. Hadjiyanakos, D. Georgakopoulou, A. Gerakis, J.
Parasiris, G. Bagiatoudi, and A. Billis, Division of Nephrology, Evan-
gelismos Hospital, Athens, Greece. Catheter exit-site (ES) and/or sub-
cutaneous tunnel (ST) infection is one of the most common causes of
peritoneal catheter removal in patients (pts) receiving CAPD. We stu-
died retrospectively 34 pts (1 SM, 1 9F), 15 to 78 years old, who deve-
loped this complication and accounted for 25% of all pts who started
CAPD from May 1983 to August 1991. These pts developed 46 episo-
des of infection affecting the ES (25 episodes in 20 pts), the ST (10
episodes in 9 pts) or both (11 episodes in 5 pts). In 39 episodes (85%)
the responsible microorganisms were staphylococci (aureus 14, epi-
dermidis 8) or pseudomonas (10), while in 7 episodes (15%) the cultu-
res were sterile. The initial treatment consisted of empirical or culture
based administration of antibiotics and careful local cleaning of the
ES (conservative therapy); however, if the infection persisted for mo-
re than 7-10 days "deroofing" of the tunnel and "d 'pilation" of the
distal cuff was also performed and finally in cases of resistant perito-
nitis, the catheter was replaced. Twenty one out of 30 episodes of ES
infection (70%) were treated by conservative therapy and seven (23%)
by "depilation" of the distal cuff, while in two episodes (2 pts) the
catheter was replaced. Twelve out of 16 episodes (75%) of the ST in-
fection were treated by distal cuff "depilation" and in the remaining 4
the catheter was replaced. In conclusion, conservative therapy and
distal cuff "depilation" was an effective treatment in 87% of episodes
of ES and/or ST infection, while the catheter was replaced in a small
percentage of pts.
Study of the metabolic status of patients on CAPD in relation to the
PE test. Th. Pliakogiannis, F. Papoulidou, Ch. Chatzidimitriou, Th.
Tsalkidou, and K. Kalaitzidis, Nephrology Clinic, General Hospital of
Kavala, Greece. The aim of this study was the ev luation of the meta-
bolic status of 29 patients, diabetic or non-diabi tic, on CAPD. The
patients were divided into two groups according to the results of the
Fast Peritoneal Equilibration Test (Twardowsii): High Absorbers
(CAPD-H) n 19 and Low Absorbers (CAPD-L) n = 10. The results
are shown on the following tables:
PE-test
Time
Age CAPD
Body wt
Kgr
% Rel.
Body wt
Great.
mg%
CAPD-H 58±9 16±7 68±14 111±20 11.5±2.6
CAPD-L 64±6 9±5 81±21 120±22 12.2±3.4
PE-test
Prot.
UNA (g)
Urea
mg% Dkcal
Gluc.
mg%
CAPD-H 62±8 114±40 520±90 145±52
CAPD-L 67± 12 142±43 430±50 127±41
PE-test HbA1 %
Pr. Loss
g/24hr KT/V
Album.
g%
CAPD-H 7.8± 1.1 9.7±4.4 2.1 3.7±0.5
CAPD-L 7.5± 1.3 6.2±2.0 1.7±0.6 3.8±0.4
PE-test CHOL/HDL
HDL
mg%
CHOL
mg%
TRG
mg%
CAPD-H 7.13±1 26±5 185±50 170±89
CAPD-L 9.36±3 24±3 217±68 265±99
Prot. (UNA): Protein intake as calculated by Urea Nitrogen Appea-
rance (UNA).
Dkcal: Daily caloric intake from dialysate.
Pr. Loss: Daily protein loss into the dialysate.
The conclusions are summarised as follows:
1) The age of the CAPD-H group was significantly lower than the
CAPD-L group (p <0.05) and the time on CAPD was significant-
ly longer in the CAPD-H group than the CAPD-L group (p <
0.01).
2) The KT/V dialysis index did not differ significantly between the
two groups.
3) Diabetic patients only presented with HbAI values above normal.
4) The CAPD-H group had greater protein loss into the dialysate
than the CAPD-L group (p < 0.01).
5) The body weight mean values of both groups of patients were lar-
ger than the ideal body weight, irrespectively of their classification
according to the Peritoneal Equilibration Test, although the mi-
dearm muscle circumference of the majority of patients showed
mild or, in some cases, severe protein malnutrition, with no stati-
stically significant difference between the two groups.
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6) The CHOL/HDL ratio was statistically higher in the CAPD-L
group (p < 0.05), as was the mean triglyceride value of the same
group (p < 0.05). The small number of patients compells us to be
cautious in the interpreration of the results mentioned above.
Adrenal microadenomas and hypertension. Diagnostic significance
of plasma renin and aldosterone. A. Pierides, M. Zavros, A. Papanasta-
siou, P. Symeonides, Ch. Tziakouri, and A. Costeas, Nicosia General
Hospital, Cyprus. Twenty-five hypertensive patients suspicious of an
adrenal microadenoma on CT were investigated with lying and stan-
ding PRA and aldosterone measurements. Based on their endocrine,
functional characteristics 2 groups of patients were identified. Five
patients (group 1) were shown to have an aldosterone secreting ade-
noma and underwent a therapeutic adrenalectomy with resolution of
their hypertension and hypokalemia. Plasma aldosterone was signifi-
cantly high in these patients both in the lying and standing position.
(lying 75, standing 84.8 ng/dl). PRA was suppressed (0.14 lying, 0.07
nglml/hr, standing) and there was hypokalemia between 1.9 and 3.5
mEq/liter. The remaining 20 patients did not show any convincing
evidence for primary aldosteronism. PRA rose on standing (1.06 —
3.50 ng/mi/hr) and there was an appropriate aldosterone response
(15.2 — 38.7 ng/dl). No adrenalectomy was carried out in this second
group of patients and their hypertension is controlled pharmacologi-
cally.
Plasma endothelin (ET) in chronic renal failure (CRF). Th. Kara-
bourn ioti, D. Moutzouris, E. Papathanassiou, Ch. Koutsia, D. Mai-
nias, D. Emmanouel, and A. Agrafiotis, Departments of Nephrology
and Microbiology Asclepeion Hospital, Athens — Department of Neph-
rology University of Creta — Haemodialysis Unit "Dragini" Clinic,
Athens, Greece. ET is a vasoconstrictor peptide produced by the endo-
thelium of large arteries, Since the release and/or the metabolicc de-
gradation of this peptide might be altered in CRF, we have measured,
by RIA, plasma ET concentration in 18 haemodialysis (HD) patients,
before and after HD session, using a cuprophan membrane, 16 non-
HD uremic patients (plasma creatinine 6.2 1.8 mg%) and 12 nor-
mal subjects. Moreover, in 4 nephrectomies, during the operation
process, the ET arteriovenous difference was measured and was
found to be > 32°Jo, indicating renal clearance of ET. Plasma ET con-
centration was significantly elevated (p < 0.01) before HD (16.8
2.1 fmol/ml) compared with healthy controls (8.6 1.6). After HD(mean weight 2.1 0.8 kg) plasma ET level remained unchanged
(16.1 2.6), indicating no ET clearance accross the cuprophane
membrane. In the non-HD uremic patients plasma ET level (12.3
1.9) was significantly (p < 0.05) higher than in controls and lower
than in HD patients. In these patients there was a significant correla-
tion between serum creatinine and plasma ET concentration (r =
0.65). On the contrary, there was no relationship between plasma ET
level and arterial pressure (r 0.12) in all the cases of this study. Our
data demonstrated that: 1) There is a relationship between the degree
of CRF and the plasma ET level. 2) ET is cleared by the kidney but
not by the cuprophan membrane, thus the HD patients present the
highest ET level. 3) There is no relationship between plasma ET con-
centration and arterial pressure and 4) The influence of ET on CRF
patients has to be elucidated.
The influence of parathyroid hormone (PTH) on platelet-activating
factor (PAF) blood levels in hemodialysed patients. Chr. Iatrou1, S. An-
tonopoulou2, N. Andricopoulos3, S. Moutafisi, G. Tsoufakis', K. Hara-
labopoulos4, CA. Demopoulos2, and P. Zirogiannis', 'Dept. of Neph-
rology, General Hospital of Athens, 2Dept. of Chemistry, University of
Athens, - Chemical Dept. of Social Insurance Foundation, 4Dept. of
Experimental Physiology, University of loannina, Greece. Bleeding
has been considered as one of the clinical manifestations of uremia.
Among the factors which are incriminated for it, is the reduction of
platelet aggregation. As far as the last is concerned the high levels of
PTH (because of the secondary hyperparathyroidism) which was
found to inhibit the platelet aggregation in response to agonist such as
ADP, arachidonic acid and PAF in vitro. In this work we have stu-
died the PTH influence on PAF levels in blood from hemodialysed
patients (HDpts). In 8 HDpts with severe secondary hyperparathyroi-
dism PAF levels in blood as well as intact PTH (iPTH) and calcium
before and 10 days after parathyroidectomy (PTHx) were measured.
Native PAF was isolated from the blood, purified by chromatography
and high pressure liquid chromatography (HPLC) and quantified by
bioassay. iPTH was measured by Allegro RIA and Ca by CIBA-
CORNING method. Our results are indicated in the table.
PAF y/5m1 blood iPTH Calcium
Before PTHx l.126x10—4 8.59x10—5 876.25 504.7 9.97 0.38
After PTHx 1.464x10—5 1.l4xlO—5 121.44 80.1 8.37 0.35
0.05 < p < 0.1 0.001 < p < 0.01 p < 0.001
In conclusion: 1) PAF levels in blood from HDpts as well as iPTH
and calcium are higher before PTHx, 2) Using stepwise regression
analysis it seems that PAF depends on calcium which depends mainly
on iPTI-1, 3) The high PAF levels before PTHx probably desensitize
the platelet PAF receptors and so decrease the platelet aggregation in
vjvo in HDpts.
Cascade lipidapheresis as therapeutic modality in the treatment of
familiar hypercholesterolemia (FH). E. Hinari, C. Balodimos, A. Psilo-
panagiotis, V. Papachrjstopoulos, D. V. Vlahakos and I. G. Vlachojan-
nis, Division of Nephrology, Patra University Hospital, Patra Universi-
ty School of Medicine, Rio, Greece. Patients homozygous for FH are
often resistant both in dietary modifications and medical therapy and
usually succumb prematurely (<30 years of age) from myocardial in-
farctions. Plasma exchange therapy, as adjunctive therapeutic moda-
lity in the treatment of this syndrome was introduced in 1975. Since
then, new methods for selective LDL lipidapheresis have been deve-
loped and tried. In the present communication, we describe our expe-
rience from the use of cascade lipidapheresis, in the treatment of a
24-year-old women with FH. Patient has been noted to have xantho-
matosis since the age of 7. Two years ago, she was evaluated at NIH,
USA, where she underwent an one-vessel prophylactic coronary by-
pass and placed on 1 gr probucol and 40 mg lovastatin daily. At the
same time, a schedule of biweekly plasma exchange therapy was ini-
tiated. Upon return to Greece, one year ago, we created a left forearm
fistula and substituted once weekly 3-hour sessions of cascade lipida-
pheresis for plasma exchange. This method requires two filters: the
first filter separates the plasma (Plasmaflo OP-OS, Asahi Med. Co,
Japan), and the second one depletes it from macromolecules, inclu-
ding lipoproteins (Cascadeflo AC-i 770, Asahi Med. Co, Japan). The
following table summarizes the variations in metabolic parameters
before and immediately after the sessions of cascade lipidapheresis
(mean SEM):
Before After n p
Cholesterol (mg/dl) 483 19 213 Il 18
Triglycerides (mg/dl) 155 23 116 12 18
LDL (mg/dl) 393 38 177 18 7 *
HDL (mg/dl) 27 3 18 4 7 t
Serum proteins (g/dl) 6.6 0.1 5.1 0.1 18 ''
Albumin (g/dl) 4.3 0.1 3.8 0.01 18 **
Despite the initial decline, lipoproteins return to pre-lipidapheresis
levels within 4-5 days. By contrast, immunoglobulins, albumin and
total serum protein return to normal within 24h. During the past year
in our center, the cell blood counts remained normal, the LV func-
tion, evaluated by radionuclide scan at rest and after exercise was wit-
hin the normal limits and achilles tendon diameter, as an index of
xanthomatosis, decreased from 3.8 cm to 2.5 cm (measured on CT
scan). In conclusion, cascade lipidapheresis appears to be a safe and
effective method in the treatment of FH.
The clinical significance of blood urea values and KT/V index in the
assessment of the adequacy of hemodialysis. M. Tjiamalis, G. Metaxa-
tos, Th. Apostolou, A. Gerakis, A. Mantjou, B. Margellos, I. Antono-
poulou, K. Katsouri, and A. Billis, Division of Nephrology, Evangelis-
mos Hospital, Athens, Greece. The adequacy of hemodialysis was pro-
spectively studied in 25 patients (pts), 42 to 73 years old, undergoing
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hemodialysis for 8 to 120 (mean 48.7) months. Eighteen pts were anu-
nc and 7 had a residual creatinine clearance of 0.5 to 6.9 mI/mm.
Dialysis was performed in 4-hour sessions once (1 pt), twice (9 pts) or
three times (15 pts) per week. In all pts the following parameters were
determined: a) the protein catabolic rate (PCR), b) the time average
concentration of blood urea (TAC), c) the KT/V index, d) the per cent
reduction of blood urea concentration during hemodialysis (PRU),
and e) the correlation between TAC of urea and the mean concentra-
tion of pre-and post-dialysis blood urea. The PCR was normal with a
mean SD of 1.08 0.16 g/kg body wt. The TAC of urea (mean
value 125.4 20.6 mg%) was slightly increased (140-150 mg%) in 4
pts and considerably increased (192 mg%) in one pt. In all those 5 pts,
modification of dialysis treatment by increase of the weekly sessions
of dialysis (3 pts) or change of the dialyser (2 pts) resulted in reduc-
tion of TAC of urea to 113-128 mg%. The index KT/V (mean value
0.92 0.19) was normal (>0,90) is 15 pts and low (0.54-0.89) in the
remaining 10. The mean PRU was 57.4 8% and showed a very
satisfactory correlation with the KT/V index (r 0.97). Finally, an
equally satisfactory correlation was found between TAC of urea and
mean concentration of pre-and post-dialysis blood urea (r = 0.95). In
conclusion: 1) The determination of the indices of adequacy of hemo-
dialysis contributed to improved treatment in our pts who were recei-
ving inadequate dialysis treatment. 2) Simple measurements, like the
mean concentration of pre-and post-dialysis blood urea (as an indi-
rect index of TAC of urea) and the PRU (as an indirect index of KTI
V) may be reliable indications for the adequacy of hemodialysis treat-
ment.
Long term changes in tumor markers in chronically hemodialyzed
patients. N. Zerefos, G.E. Digenis, M. Christophoraki, V. Papanto-
niou, I. Grapsa, P. Rapini, and H. Gyftaki, Hemodialysis Unit and
Radio-isotope Section of "Alexandra" Hospital, Athens, Greece. In or-
der to evaluate the long term changes of the levels of certain tumor
markers, [AFP, CEA, CA-125 (ovaries), CAI9-9 (pancreas) and
CAl 5-3 (breast)1, sera from 12 stable non smoking patients on regular
hemodialysis (mean duration 78 6.9 months, x SEM) were ex-
amined at the beginning of the study (A) and 27 months later (B), by
the same radio-immuno assays. None of them showed any signs or
symptoms of neoplasia, and pre-dialysis serum creatinine levels re-
mained stable during this period. The comparison was made between
the two measurements and a group of 50 normal adults (C).
AFP
(ng/ml)
CEA
(ng/ml)
CAI9-9
(U/mi)
CA-125
(U/mI)
CAI5-3
(U/mi)
C 0.9 0.2 2.2 0.1 15.8 1.0 19.7 1.3 12.8 0.4
A 9.4 0.4 5.9 1.0 10.5 1.3 19.1 3.5 14.7 0.7
B 4.3 1.3 7.2 2.8 26.5 7.0 22.2 2.2 15.1 0.9
p (A-B) < 0.01 NS < 0.05 NS NS
It is obvious that serum levels of AFP were decreased and those of
CA 19-9 were increased significantly at the end of the study, while the
rest tumor markers remained stable. However, these changes did not
influence the relation of tumor markers between the hemodialyzed
patients and the normal controls. Accordingly, AFP, CEA and
CAI5-3 had higher levels while CA19-9 and CA-l25 remained nor-
mal. Conclusions: 1) By I he time on hemodialysis there are some
changes in serum levels of certain tumor markers. 2) Chronic infla-
mation of pancreas may be the cause of increased CA 19-9 levels.
Prevalence of hepatitis C antibodies (anti-HCV) in renal patients
and nursing staff. A. Gerakis, G. Metaxatos, E. Kapassouri, Th. Apo-
stolou, J. Parasiris, S. Konstantinidis. A. Gjouganatou, V. Spandida-
kis, and A. Billis, Division of Nephrology and Blood Transfusion Servi-
ce, Evangelismos Hospital, Athens, Greece. We have previously repor-
ted a high prevalence of anti-HCV not only in hemodialysis patients
(pts), but also in those treated in the wards for various nephropathies.
Extending these observations we studied the presence of anti-HCV in
324 pts (189 males, 135 females), 16 to 90 years old. Two hundred
thirty-six of these pts were hospitalized for various renal diseases, 49
were on hemodialysis (29 permanently dialysed in our unit and 20
regularly dialysed elsewhere but temporarily treated by us) and 39 we-
re on CAPD. We also studied 30 members of the nursing staff (28
females, 2 males), 19 to 52 years old. As a control group were used
4998 apparently healthy blood donors. The determination of anti-
HCV was done by enzyme-linked immuno-sorbent assay (ELISA) and
all seropositive individuals were rechecked by the recombinant im-
munoblot assay (RIBA). The percentage of seropositive persons by
the ELISA technique was 1.18 in the blood donors, 6.7 in the nursing
staff and 9.6 in the total of pts, that is, 7.2% in those treated in the
wards, 7.7% in those undergoing CAPD and 22.5% in those on hemo-
dialysis (6.9% in those permanently dialysed in our unit and 45% in
those temporarily treated by us). When the seropositive persons were
rechequed by the RIBA technique, 51% of the blood donors (30/5 9)
and 55% of the pts (17/31) were found again seropositive. There was
no correlation between the presence of anti-HCV and: a) the sex, age
or presence of hepatitis B markers among pts and nursing staff, b) the
number of blood transfusions, the serum transaminase values and the
underlying nephropathy among all pts, and c) the duration of treat-
ment in pts undergoing hemodialysis or CAPD. In conclusion: I)
Compared to the blood donors, anti-HCV were found in six-fold hig-
her percentage in pts treated in the wards for various nephropathies,
in those permanently hemodialysed in our unit or undergoing CAPD
and in the nursing staff, while the percentage of seropositivity was
even higher in pts hemodialysed in other units but temporarily trea-
ted by us. 2) Nearly half of the seropositive blood donors and pts were
found seronegative when they were rechequed by the RIBA techni-
que.
Hepatitis B, C and D in patients undergoing hemodialysis. P. Levan-
takis2, P. Dimoxenous-Birbiri3, N Georgilas', H. Yousef', M. Boukou-
vala2, and P. Evangelou', Hemodialysis Unit, General Hospital of Ver-
ia, Macedonia, Greece1, He,nodialysis Unit2 and Blood Transfusion
Service3, General Hospital of Kozani, Macedonia, Greece. We studied
the incidence of the presence of antibodies against hepatitis B, C and
D viruses in 98 patients undergoing hemodialysis (63 men and 35
women) and in 37 doctors and nurses in order to derermine the rate
of infection of patients and staff by these viruses. The determination
of the indices was done using an immunoassay in two time periods
(12 months apart) and included HBsAg, HBeAg, anti-Hbs, anti-Hbe
and antiHbc for virus B, anti-C for virus C and anti-HD for virus D.
The determination of anti-C was done with a second generation EIA
and the confirmation of the positive results was done with the EIA
supplemental assay (Abbott) and Chiron Riba HCV test of the second
generation. Our results showed that during the one-year period the
incidence of antibodies against hepatitis B did not change in either
patients or staff, with 69.35% of the patients and 83.7% of the staff,
having immunity against hepatisis B virus, We also found that
17.35% of the patients and no member of the staff were positive for
anti-HCV. None of the typical carriers of HbsAg was positive for
HDV. Eleven of the 1-ICY-positive patients were infected by HBV but
none of them was a typical carrier of HbsAg. Conclusions: 1) The risk
of hepatitis for patients undergoing dialysis has been minimized. 2)
The staff of the dialysis units do not have a greater than normal risk
of being infected by hepatitis C. 3) Hepatitis D does not seem to be a
problem at the present time in hemodialysed patients. 4) The preva-
lence of hepatitis C seems to be increasing. 5) There was a positive
correlation between HCV-positive patients and duration of hemodia-
lysis.
Rapid high efficiency hemodialysis (RHED): One year experience.
K. Sombolos, T. Natse, K. Mavromatidis, N. Zou,nbaridis, Chr. Fytili,
G. Katsiaris, and A. Karagianni, Renal Unit, General Hospital "G. Pa-
paniko!aou" Thessaloniki, Greece. Rapid (3 hours x 3 times/week)
and high efficiency hemodialysis treatment (dialyzers 1.7-2.1 m2)was
provided for one year to 7 chronic hemodialyzed patients (6M, IF,
mean age 52 years) who underwent chronic conventional hemodialy-
sis for a period ranged from 8-75 months (mean 26 months). Dialysis
machines equipped with ultrafiltration control system and bicarbona-
te dialysate (Na 137 mEq/liten, HCO3 39 mEq/liter + 5 mEq/liter ace-
tate) were used. Blood and dialysate flow rates were kept at 400 mu
mm and 600 ml/min respectively. BUN, creatinine, K, Caand pho-
sphorus blood levels during the first 6 months of RHED were compa-
red to those obtained during the previous 6 months when the patients
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received conventional hemodialysis (4 hours x 3 times/week, dialy-
zers 1-1.3 m2, dialysate acetate). Statistically significant difference, (p
= 0.004). was found only in BUN levels which showed a 14% decline
during RHED. The mean value of two measurements of urea (KT/V)
during the first 6 months of RHED was found to be 1.24. One patient
died during the 7th month of RHED. By the end of the first year the
above biochemical parameters did not show any significant difference
comparing to those of the first 6 months. It is concluded that RHED
is comparable to conventional hemodialysis.
Surgical complications in 410 renal transplantations. A. Kostakis, G.
Sotirchos, St. Kyriakidis, G. Zavos, K. Dues, Chr. Klonaris, A. Sampa-
takakis, and Gr. Vosnides, Transplantation Center, Laikon General
Hospital, Athens, Greece. From March '83 until November '91, we
performed 410 kidney transplantations (227 from living and 183
from cadaveric donors). Six pts received a second graft and another 4
received, simultaneously, a pancreatic graft. Twenty seven pts develo-
ped 28 postoperative surgical complications (vascular: 6, graft ruptu-
re: 5, lymphocele: 10, ureteric: 7). All vascular complications (1,4%),
3 arterial thromboses, 1 vein thrombosis and 2 aneurysms of the arte-
rial anastomosis — resulted to loss of the graft. All graft ruptures
(1,2%) were due to severe acute rejection and were managed with
emergency nephrectomy. All pts with lymphocele (2,4%) required sur-
gery following which graft function returned to normal. Graft func-
tion also returned to normal following-operation of all ureteric com-
plications (1,7%), ureterocystic fistula: 3 pts, ureteric obstuction: 4
pts. It is concluded that m ticu1ous operative techniques can minimi-
ze the surgical complicati )flS of kidney transplantation.
Lymphocele: a puzzling :omplication of renal transplantation. G. So-
tirchos, St. Kyriakjdjs, Sp. Garbis, G. Zavos, I. Bokos, M. Pappas, Gr.
Vosnides, and A. Kostakis, Transplantation Center, Laikon General
Hospital, Athens, Greece. Lymphocele consists a separate clinical enti-
ty in kidney transplantation. Of 410 renal transplants (237 from li-
ving and 183 from cadaveric donors) performed in our unit between
March '83 and November '91, lymphocyle requiring surgery develo-
ped in 10 (2,4%). Graft function was significantly impaired in all 10
cases. The diagnosis was made by clinical, radioisotopic and ultraso-
nographic criteria, while on several occasions puncture of the lym-
phocele was also required. Transabdominal marsupialization was per-
formed and proved effective in all cases. No recurrence was observed.
The post-operative course was normal and graft function returned to
normal in all pts apart from one with preexisting chronic rejection
who lost his graft several months later. In conclusion, we believe that
careful ligation of the lymphatics of both donor and recipient as well
as the diminution of some predisposing factors such as steroids, diu-
retics, anticoagulants, rejection episodes and ureteral obstruction, mi-
nimize the risk of developement of lymphocyles, the vast majority of
which are treated surgically.
Risk factors in renal retransplantations. D, Takoudas, A. Antonia-
dis, A. Papagjannis, D. Gakis, V. Papanikolaou, G. Vergoulas, G. Imv-
rios, G. Kyriakopoulos, and Z. Poly,nenidis, Transplantation Surgical
Clinic, Histocompatibility Department, Hippokration General Hospi-
tal, Thessaloniki, Greece. The results of kidney retransplantation
(RTx) in the cyclosporine era was retrospectively analyzed. During
the last decade, 21 out of 284 renal transplantations (Tx) were re-
transplantations (18 second, 2 third and one fourth RTx). Eighteen
patients received cadaver donor grafts while the remaining donations
were living related. HLA-DR matching was 2.5 0.7 (r : 1-4). Two
patients were retransplanted in the pre-cyclosporine era, In one
patient the graft was lost due to nonimmunologic reasons. Eight
patients (44%) were highly sensitized (PRA 5O-83%). One of them
rejected his graft, The follow up ranged from 6 to 79 months. Overall
graft survival of the remaining 18 retransplantations was 89% at 1, 2
and 3 years. Acute rejection occurred in 9/18 pts (50%) within 3
months with complete recovery in 7 (77.7%). Two patients rejected
their grafts due to acute vascular rejection (accelerated) on the 7th
postoperative day. Both of them had rejected their first graft on 10th
day and I month post Tx. One pt who rejected his second graft on
12th day and 3 pts with primary nonfunction of their first graft had
successful retranspiantations. In conclusion with the advent of
cyclosporine retransplantations can be safely performed. The survival
of first grafts and the reasons of their loss seem to influence their
outcome. In contrast the PR.A levels do not influence their outcome.
Kaposi's sarcoma in renal transplantation. C. Dioudis, D. Grekas,
M. Daniilidjs, G. Karkavelas, P. Alivanis, V. Derveniotis, and A. Tour-
kantonis, First Medical Department, Renal Unit, University Hospital
AHEPA, Thessalonikj, Greece. The appearance of Kaposi's sarcoma
after renal transplantation is frequent among Mediterranean people.
In the present study we present four cases of Kaposi's sarcoma out of
162 patients who received transplants. There were 3 men and 1 wo-
man aged from 30 to 60 years. The disease was observed to range
between 9 months and 125 months after renal transplantation and
developed mainly on the upper and lower extremities and the oral
mucosa. Two patients were under immunosuppression with CyA +
MPZ; one patient received CyA + AZA + MPZ and the last patient
AZA + MPZ. The ratio CD4/CD8 was lower than 0.9 in 3 patients.
Antibodies against HBV, HSV, HIV, CMV, EBV were detected in no-
ne of these three patients. One patient had IgG antibodies against
CMV and EBV but there was no reactivation. The diminution of im-
munosuppression in two patients led to regression and in some cases
the disappearance of the extensive cutaneous Kaposi's lesions. The
patient with the visceral location died six months later and the last
patient showed no improvement. Conclusion: Kaposi's sarcoma after
renal transplantation is frequent and it is possibly related to overim-
munosuppression.
Effect of theophylline on erythrocytosis after renal transplantation.
D. Grekas, C. Dioudis, D. Valkouma, P. Alivanis, V Derveniotis, and
A. Tourkantonis, First Medical Department, Renal Unit, University
Hospital AHEPA, Thessaloniki, Greece. Erythrocytosis occurs in 10-
15% of renal transplant recipients, and there is evidence that the pro-
duction of erythropoietin is modulated by adenosine. We prospecti-
vely evaluated the effect of theophylline, a nonselective adenosine an-
tagonist, in eight patients with erythrocytosis after renal transplanta-
tion. All patients were given triple drug immunosuppressive therapy
with methylprednisolone (8 mg/day), azathioprine (1,5-2 mg/kg body
wt daily) and Cyclosporine A (4 mg/kg body wt daily), After an eight-
week course of theophylline erythropoietin levels were significantly
reduced (from 61 mIU/ml before to 16.5 mlU/ml after treatment, p
< 0.05). Also, the hematocrits were reduced from 0.59 before to 0.51
after treatment (p < 0.05). The previous requirement of monthly
phlebotomy was eliminated in all transplant recipients. The above ef-
fects were reproducible when the patients were rechallenged with
theophylline after a recovery period. It is suggested that theophylline
attenuates the production of erythropoietin in patients with erythro-
cytosis after renal tranplantation and may be useful in the treatment
of this condition.
Influenza vaccination in transplants and patients on regular haemo-
dialysis. D. Grekas, P. Alivanis, V. Kyriazopoulou, C. Dioudis, A. Siou-
lis, V. Derveniotis, and A. Tourkantonis, First Medical Department,
Renal Unit, University Hospital AHEPA, Thessaloniki, Greece. Since
immunosuppressed patients are at higher risk of serious influenza vi-
rus infection than healthy subjects we decided to study the effective-
ness of influenza vaccination on renal transplant patients, despite the
theoretical aspect that such treatment could induce glomerular les-
sions through an immunological process. Forty transplant patients
with satisfactory renal graft function and no febrile episodes, aged
from 20 to 50 years were studied. Blood samples were collected befo-
re the intramuscular injection of 0.5 ml of multivalent influenza vac-
cine (Pasteur Merieux Serum Vaccins) and one and two months after
the vaccination. Before vaccination the antibody titers to influenza
virus ranged from 0 to 1/20 and after vaccination from 1/20 to 1/320.
One month after vaccination 17/40 (42.5%), 19/31 (58%) and 16/33
(48%) patients showed a four fold or greater increase of serum in-
fluenza antibody titers to antigens A/H3N2, AJH1N1 and B respecti-
vely. A similar response at two months in relation to the first month
response rate after vaccination was found in 15/17 (88%), 18/18
(1 00%), and 15/16 (93%) of transplant patients for the above mentio-
ned three antigens. Side effects observed in two of studied patients.
Serum creatinine, urine protein and the rate of acute graft rejection
were not changed. It is suggested that influenza vaccination is safe
and quite effective in renal transplant patients.
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Postoperative complications of the use of peritoneal catheter, Toron-
to-Western Hospital (TWH) in continuous ambulatory peritoneal dia-
lysis (CAPD). Experience in 130 catheters. N. Apostolidis, A. Katirt-
zoglou, A. Manouras, E. Prassa, and Th. Mouniokalakis, A ' Propae-
deutic Surgical Clinic and B' Dept. of Internal Medicine, University of
Athens, Medical School, Hippokralion Hospital, Athens, Greece.
CAPD is an acceptable method in the management of the end-stage
chronic renal failure. Apart from minimal complications this method
offers an advantageous long-term approach in the management of
these patients. During 1982-1991, 130 TWH catheters were inserted
in 115 patients (CRF). The duration of treatment by this method ran-
ged from Ito 108 months (x = 29.5). In most patients the insertion of
catheter was done under general anaesthesia. The incisions used were
transverse paraumbilical (68 pts), lower midline (45 pts), paramedian
(13 pts) and high Roux (4 pts). Early postoperative complications we-
re: peritoneal fluid leaking 12 (9.2%), one way obstruction 2 (1.5%)
and evisceration 1 (0.8%). Late complications were: peritoneal fluid
leaking 16 (12.3%), herniation 14(10.8%), tunnel infection 13 (10%),
protrusion of cuff 7 (5.4%) and small bowel perforation 1 (0.8%). In
conclusion: I) TWH catheters show minimal postoperative complica-
tions. 2) Postoperative herniation depends on the incisional ap-
proach, with the transverse paraumbilical one, succeeding better re-
sults. 3) Moreover this approach seems to be generally associated with
the least postoperative complications.
Early and late function of Tenckhoff catheters placed surgically or by
trocar for chronic ambulatory peritoneal dialysis (CAPD). N. Nikolo.
pou!ou, B. Margellos, S. Klimopoulos, Chr. Christodoulidou, A. Gera-
kis, Th. Apostolou, S. Konstandinidis, K. Ouzounidou, and A. Billis,
Division of Nephrology, Evangelismos Hospital, Athens, Greece. Non-
surgical, by trocar, insertion of the Tenckhoff catheter is simple and if
there is enough experience, can be favorably compared to the surgical
technique. However, very few studies have compared the use of both
techniques by the same center. We studied therefore, the early and
late results of these techniques in 135 consecutive patients (pts) (83
males, 52 females), 14 to 82 years old, who were started on CAPD
during an 8-year period. In 85 pts, the catheter was surgically placed
(group I) and in the remaining 50 pts, it was inserted by trocar (group
II). In all pts a straight radio-opaque catheter with two dacron cuffs
was used. Surgical placement was done by midline incision under lo-
cal anesthesia, while the insertion by trocar was done also in the mid-
line 2 cm below the umbilicus. The two groups of pts were compara-
ble in sex, age, primary renal disease and mean follow-up period
which was 32.6 months for group I and 29.9 months for group II. The
main early complication was leakage of the dialysate which occured
in 13.1% of pts in group land in 3.6% of those in group II and was
treated conservatively in all pts. The most common late complica-
tions in pts of group I were hernias, infections of the exit-site or the
subcutaneous tunnel and replacement of the catheter due to obstruc-
tion or migration (p =NS),while in pts of group II not a single case of
hernia at the insertion site of the catheter was observed. The number
of episodes of peritonitis/pt/year was equal (0.63) in both groups, The
cummulative functional survival of the catheter at 5 years was 84%
for group I and 70.6% for group II. In conclusion, Tenckhoff catheters
which were placed in our pts either surgically or by trocar, showed a
satisfactory early and late function, but the insertion by trocar resul-
ted in a smaller percentage of early (leakage of dialysate) and late
(hernias) complications.
Removal of Tenkchoff catheter and immediate placement of a new
one in patients with persisting or recurring peritonitis undergoing
CAPD. D. Hadjiyannakos, N. Nikolopoulou, B. Margellos, G. Metaxa-
tos, A. Gerakis, D. Georgakopoulou, M. Giamalis, Chr. Kaninis, and
A. Billis, Division of Nephrology, Evangelismos Hospital, Athens,
Greece. For the treatment of persisting or recurring microbial perito-
nitis in patients (pts) on CAPD, Tenckhoff catheter is usually remo-
ved, the pt is temporarily transfered to hemodialysis and, after the
control of the infection, a new catheter is inserted. However, certain
authors have reported a successful treatment of peritonitis by remo-
val of the catheter and immediate placement of a new one. We used
this technique in 7 pts, 38 to 65 years old, with refractory to treat-
ment (3 pts) or recurring (4 pts) peritonitis. Patients who were sub-
mitted to catheter replacement for peritonitis, but also presented with
infection of the exit site and/or of the subcutaneous tunnel, were ex-
cluded from the study. The peritoneal fluid cultures, which were ta-
ken before the removal of the catheter, showed staphylococcus (au-
reus 2 pts, epidermidis 1 pt), pseudomonas (1 pt) and acinetobacter (1
pt), while in 2 pts were sterile. The removal of the catheter and the
placement of a new one, were performed sequentially at the same ti-
me so that peritoneal dialysis was uninterrupted, allowing also the
intraperitoneal administration of antibiotic drugs. Following replace-
ment of the catheter, resolution of peritonitis was achieved in all pts
and the peritoneal fluid cultures became negative. During the follow-
up period, which ranged from 3 to 31 months, there were only 3 epi-
sodes of peritonitis in three pts which occurred 6, 16 and 27 months
after replacement of the catheter. In conclusion, in cases of persisting
or recurring peritonitis, the removal of Tenckhoff catheter and the
immediate placement of a new one is an effective therapeutic ap-
proach which also obviates the need of an additional intervention for
insertion of the catheter and of temporary transfer of patient to he-
modialysis.
Sclerosing peritonitis in patients on continuous ambulatory perito-
neal dialysis (CAPD). B. Margellos, N. Nikolopoulou, S. Klimopoulos,
D. Georgakopoulou, G. Metaxatos, T. Apostolou, C. Christodoulidou,
D. Hadjiyannakos, and A. Billis, Division of Nephrology, Evangelis-
mos Hospital, Athens, Greece. Sclerosing peritonitis (SP) is the most
serious late complication of CAPD and its incidence, clinical manife-
stations and mortality vary widely in the literature. We studied retro-
spectively 11 patients (pts) 34 to 63 years old, who developed this
complication and accounted for 8% of all pts who were started on
CAPD during a 7-year period. The primary renal disease was chronic
interstitial nephritis (5 pts), glomerulonephritis (3 pts), malignant hy-
pertension (1 pt)and unknown (2 pts). Lactate solutions were used in
6 pts and acetate in 5 pts. The incidence of episodes of peritonitis in
those pts (1/14.3 months/pt) did not differ significantly from that of
the other CAPD pts (1/19.5 months/pt, p> 0.05). Eight pts received
aminoglycosides intraperitoneally. The main clinical manifestations
were progressive loss of ultrafiltration (8 pts), recurrent episodes of
obstructive ileus (5 pts), persistent vomiting (3 pts), progressive ca-
chexia (3 pts), diarrhea (3 pts) and ascites (2 pts) and all of them ap-
peared 6-88 months after the initiation of CAPD. All pts were treated
by laparotomy (9 of them while they were on CAPD and 2 after they
had been transfered to hemodialysis) during which lysis of adhesions
(2 pts), with (5 pts) or without (2 pts) placement of a new catheter and
removal of the catheter (4 pts) was performed. At the end of the fol-
low-up period (November 1991) 6 pts were still on dialysis (hemodia-
lysis 3, CAPD 3), 1 to 50 months after the diagnosis of SP, 1 pt had a
successful renal tranplantation and 4 pts had died (two postoperative-
ly and two 45 and 51 months after the diagnosis of SP). In conclusion:
1) The incidence and mortality of SP in our pts were among the lo-
west reported in the literature. 2) We believe that prompt surgical
treatment was most important for their survival and allowed the con-
tinuation of CAPD in some of them.
